Hindawi Evidence-Based Complementary and Alternative Medicine Volume 2020, Article ID 3219840, 17 pages https://doi.org/10.1155/2020/3219840

# Research Article

# Screening for a Potential Therapeutic Agent from the Herbal Formula in the 4<sup>th</sup> Edition of the Chinese National Guidelines for the Initial-Stage Management of COVID-19 via Molecular Docking

# Yue Sun, Angela Wei Hong Yang, Andrew Hung, and George Binh Lenon

<sup>1</sup>School of Health and Biomedical Sciences, RMIT University, Melbourne 3083, Australia <sup>2</sup>School of Science, RMIT University, Melbourne 3083, Australia

Correspondence should be addressed to George Binh Lenon; george.lenon@rmit.edu.au

Received 4 March 2020; Accepted 12 August 2020; Published 24 December 2020

Academic Editor: Yukihiro Shoyama

Copyright © 2020 Yue Sun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. COVID-19 caused by SARS-CoV-2 infection has been spreading through many countries since the end of 2019. The 4<sup>th</sup> edition of the national guidelines for the management of COVID-19 provides an herbal formula with 9 herbs for its management. Aim of Study. We aimed to predict the mechanism of binding of SARS-CoV-2 and SARS-CoV spike glycoproteins with angiotensinconverting enzyme 2 (ACE2) to provide a molecular-level explanation of the higher pathogenicity of SARS-CoV-2 and to identify protein sites which may be targeted by therapeutic agents to disrupt virus-host interactions. Subsequently, we aimed to investigate the formula for the initial-stage management to identify a therapeutic agent with the most likely potential to become pharmaceutical candidate for the management of this disease. Materials and Methods. GenBank and SWISS-MODEL were applied for model creation. ClusPro was used for protein-protein docking. PDBePISA was applied for identification of possible binding sites. TCMSP was employed for identification of the chemical compounds. AutoDock Vina together with PyRx was used for the prediction and evaluation of binding pose and affinity to ACE2. SwissADME and PreADME were applied to screening and prediction of the pharmacokinetic properties of the identified chemical compounds. PyMOL was used to visualise the structural models of SARS-CoV-2 and SARS-CoV spike glycoproteins complexed to ACE2 and to examine their interactions. Results. SARS-CoV-2 had two chains (labelled chains B and C) which were predicted to bind with ACE2. In comparison, the SARS-CoV had only one chain (labelled chain C) predicted to bind with ACE2. The spike glycoproteins of both viruses were predicted to bind with ACE2 via position 487. Molecular docking screening and pharmacokinetic property prediction of the herbal compounds indicated that atractylenolide III (-9.1 kcal/mol) from Atractylodes lancea (Thunb.) Dc. (Cangzhu) may be a candidate therapeutic agent for initial-stage management. Conclusions. Attractylenolide III is predicted to have a strong binding affinity with ACE2 and eligible pharmacokinetic properties, anti-inflammatory effects and antiviral effects in in vitro study, and high distribution on the lungs in in vivo study.

# 1. Introduction

Coronavirus can cause multiple system infections including respiratory, digestive, and neurological systems in humans and other mammals [1]. The novel variant SARS-CoV-2 belongs to the subfamily of beta coronavirus. This makes the new virus the third zoonotic human coronavirus identified in this century. The last two zoonotic human coronaviruses which wreaked havoc in the global health system in the last

two decades were the severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) [2]. The mortality rates were 10% for SARS-CoV and 37% for MERS-CoV [3]. The most up-to-date reports from the World Health Organization (WHO) showed that the SARS-CoV-2 epidemic has infected 13,876,441 people and claimed 593,087 lives worldwide at the time of writing [4]. According to the Chinese Guideline for Diagnosis and Treatment of SARS-

CoV-2 Infection (Trial version 4), in most of the cases, the common symptoms are fever, drowsiness, and dry cough. In severe cases, serious symptoms may rapidly emerge, including acute respiratory distress syndrome, septic shock, metabolic acidosis, and coagulopathy. The susceptive groups are young children and elderly people [5]. Since the beginning of this epidemic, researchers have focused on new medications that could show potential to contain the transmission of the new virus and management of its collateral symptoms. The 4th edition guidelines included the treatment including Chinese herbal medicine with 3 formulas to target 3 different stages of this disease. The symptoms in the initial stage of this disease are mild and relatively easy to manage compared to the severe stage. Herein, we aimed to investigate the modified herbal formula (Magnificent Atractylodes Rhizome powder; 神术散) designated for the management of the initial stage of this disease, namely, the stage of cold dampness stagnation in the lung, in Chinese medicine. It contains 9 herbs including Atractylodes lancea (Thunb.) Dc. (Atractylodes Rhizome; Cangzhu), Citrus reticulata Blanco (dried tangerine peel; Chenpi), Magnolia officinalis Rehd. et Wils. (Officinal Magnolia Bark; Houpo), Agastache rugosa (Agastaches Herba; Huoxiang), Amomum tsaoko Crevost et Lemarie (tsaoko fruit; Caoguo), Ephedra sinica Stapf (ephedra; Mahuang), Notopterygium franchetii H. de Boiss. (Incised Notopterygium Rhizome or Root; Qianghuo), Zingiber officinale Roscoe (fresh ginger; Shengjiang), and Areca catechu L. (areca seed; Binglang). The dosages of the ingredients are 15 grams for Atractylodes lancea (Thunb.) Dc., 6 grams for both Amomum tsaoko Crevost et Lemarie and Ephedra sinica Stapf, and 10 grams for the rest of ingredients [5]. However, scientific evidence is presently lacking to justify the claim of its effectiveness for the management of this disease.

The angiotensin-converting enzyme 2 (ACE2) receptor is viewed as the key protein in humans for the development of SARS-CoV-induced lung injury [6]. Since SARS-CoV-2 may target the same receptor to induce lung injury, it is proposed that computational molecular docking analysis is a feasible and rapid strategy to apply for the analysis of the interaction mechanism between the virus' spike glycoprotein and ACE2 receptor. However, there is presently no experimentally obtained structural model of the SARS-CoV-2 spike glycoprotein deposited yet in the Protein Databank (PDB) (http://www.rcsb. org). Despite several published and ongoing studies performed using docking analysis for the virus' proteins and ligands, the protein models applied in previous studies are based on the protein models from the SARS-CoV virus. However, the genetic data of the new viruses are available from GenBank (https://www.ncbi.nlm.nih.gov/genbank/). Therefore, in this study, we have modelled the spike glycoprotein of SARS-CoV-2 to examine the difference between SARS-CoV-2 and SARS-CoV and, in particular, to provide a molecular-level understanding of the difference in transmissibility and pathogenicity of SARS-CoV-2 compared to SARS-CoV.

### 2. Materials and Methods

The binding sites of the binding complex of the spike glycoprotein of both viruses and ACE2 were identified. The chemical

compounds from these 9 herbs were explored for their binding affinities with ACE2. Finally, the identified chemical compounds were screened for their pharmacokinetic properties including ADME and toxicity to find a therapeutic agent with good potential to be a pharmaceutical candidate.

2.1. Model of the Binding Complex of SARS-CoV-2 Spike Glycoprotein and Angiotensin-Converting Enzyme 2. The genetic information of SARS-CoV-2 spike glycoprotein in PubMed with accession number as YP 009724390.1.1 was extracted into a FASTA format file. This sequence was used as input data for homology modelling in SWISS-MODEL (https://swissmodel.expasy.org/). Among the results, Model 2 was selected because of the high values of Coverage, GMQE, and QMEAN. Further detailed information is presented in the Supplementary SWISS-MODEL building result file and structure assessment file. The ACE2 protein structure was extracted from the Protein Data Bank with the PDB ID 1R4L in the PDB format. The ClusPro online server (https://cluspro.bu.edu/queue.php) was applied to perform protein-protein docking for SARS-CoV-2 spike glycoprotein and ACE2. Model 0 was selected out of the top 10 models in the balanced order (Supplementary ClusPro protein-protein docking file). The complex structural model was created and visualised using PyMOL Molecular Graphics System, Version 1.2r3pre, Schrödinger, LLC., with various colours applied to label the different chains of these two proteins to facilitate visualization and interpretation.

2.2. Model of the Binding Complex of SARS-CoV Spike Glycoprotein and Angiotensin-Converting Enzyme 2. The binding complex of these two proteins was extracted from Protein Data Bank with PDB ID 6ACG (https://www.rcsb.org/structure/6ACG) in PDB format. The structural model was created and visualised using PyMOL with various colours applied to label the different chains of these proteins to facilitate interpretation.

2.3. Identification of Binding Chains and Binding Sites of the SARS-CoV-2/SARS-CoV Spike Glycoproteins and Angiotensin-Converting Enzyme 2. PDBePISA (https://www.ebi.ac. uk/pdbe/pisa/) was employed for the identification of binding chains and binding sites of the SARS-CoV-2/SARS-CoV spike glycoproteins and ACE2. The interface result and hydrogen bonds are summarized in Table 1. The binding chains for the interactions of these two proteins were acquired from the interface result, while the binding sites were obtained from the results of the hydrogen bond analysis. Further detailed information is presented in the supplementary files with the file names as follows: SARS-CoV-2 and ACE2 interface results, SARS-CoV-2 chain B and ACE2 (chain D) binding sites result, SARS-CoV-2 chain C and ACE2 (chain D) binding sites result, SARS-CoV and ACE2 interface results, and SARS-CoV chain C and ACE2 (chain D) binding sites results. The above-identified binding chains and binding sites from these two viruses were compared to elucidate the similarity and difference.

 $\Delta iG$  (P value) Structure 1 Structure 2 Interface area (A<sup>2</sup>) ΔiG (kcal/mol) Chain B Chain C 5285.6 -45.90.707 Chain A Chain B -42.80.722 5263.4 Chain A Chain C 5248.1 -41.70.781 Chain D (ACE2) Chain B 830.3 -11.20.341 Chain D (ACE2) Chain C 712.7 -5.30.666

TABLE 1: PDBePISA interface result of SARS-CoV-2 spike glycoprotein and angiotensin-converting enzyme 2 (chain D).

TABLE 2: The scientific names, pinyin names, and Chinese character names of the herbs.

No.	Scientific names	Pinyin names	Chinese character names in TCMSP
1	Atractylodes lancea (Thunb.) Dc.	Cangzhu	
2	Citrus reticulata Blanco	Chenpi	陈皮
3	Magnolia officinalis Rehd. et Wils.	Houpo	厚朴
4	Agastache rugosa	Huoxiang	藿香
5	Amomum tsaoko Crevost et Lemarie	Caoguo	草果
6	Ephedra sinica Stapf	Mahuang	麻黄
7	Notopterygium franchetii H. de Boiss.	Qianghuo	羌活
8	Zingiber officinale Roscoe	Shengjiang	生姜
9	Areca catechu L.	Binglang	槟榔

2.4. Identification of Chemical Compounds from Designated *Herbs.* The TCMSP server (http://tcmspw.com/tcmsp.php) is an open online database with a large number of herbal entries with ADME properties, providing phytochemical information [7]. The Chinese character names of the identified herbs were used as input data for the search (Table 2). The chemical compound results of each herb were screened by the designed selection criterion, namely, that the logP value is not more than 3. This is based on the theory that logP values of 2-3 had been recommended as the cutoff value for hydration, which has been established as a benchmark for the solubility of compounds [8]. The results were saved as PDB files via PubChem for further analysis. Chemical compounds without PubChem ID were extracted directly from the database. The chemical structures of the compounds with strong binding affinities (≥9 kcal/mol) are summarized in Table 3 in Results. The chemical structures for the compounds with binding scores in the range of -7 kcal/mol to -9 kcal/mol are presented in the supplementary table.

2.5. Molecular Docking of the Chemical Compounds with Angiotensin-Converting Enzyme 2. The PyRx software was applied with AutoDock Vina for molecular docking. The binding affinity values are summarized in the spreadsheet in Excel file format (Supplementary docking result file). Molecular docking was performed using AutoDock Vina version 1.1.2 [9] (The Scripps Research Institute, La Jolla, CA, USA). The docking Graphical User Interface (GUI) frontend PyRx version 0.8 (https://pyrx.sourceforge.io/) (The Scripps Research Institute, La Jolla, CA, USA) was used to prepare all protein and ligand files for docking and for the generation of docking parameter input files. PyRx was employed to convert all protein and ligand PDB files into PDBQT format. Protonation states for titratable sidechains of the protein were based on those assigned using OpenBabel (OpenEye Scientific Software, Santa Fe, NM, USA) at pH 7. Gasteiger

charges were applied to protein and ligands. Docking boxes were set using the "maximise" option in PyRx around the protein receptor in order to enable "blind" docking, in which the entire protein surface and accessible interior pockets were made available for potential binding of ligands. All dockings were performed with the default exhaustiveness value of 8. The dockings were semirigid, with full torsional flexibility allowed for the ligands, while the protein receptor structures were kept fixed. The cutoff value used to define strong binding affinity was set to be equal to or more than 7.0 kcal/mol. Therefore, the compounds with binding affinity values higher than this value were excluded for further study.

2.6. Text Mining for the Antiviral Activity of Identified Chemical Compounds. The identified chemical compounds with binding affinity (≥7.0 kcal/mol) were searched in PubChem for antiviral activity evidence from bioassay results. The chemical compounds with active results from bioassay studies against respiratory infection virus that have similar symptoms with COVID-19 were summarized with the minimal concentrations, study types, and references provided in Table 4.

2.7. Pharmacokinetic Property Screening and Prediction. The identified chemical compounds in PDB format were translated into MOL files using ChemDraw 3D version. SwissADME (http://www.swissadme.ch/) and PreADME (https://preadmet.bmdrc.kr/) were applied to predict pharmacokinetic properties including absorption, distribution, metabolism, and excretion (ADME) and toxicity. The results are summarized in a supplementary screening and prediction of ADME and toxicity table in terms of water solubility, Pharmacokinetic, Druglikeness, Medicinal Chemistry, Toxicity, and Eligibility. The screening criteria dictate that the chemical compound must be water-soluble, have high gastrointestinal absorption, satisfy Lipinski rule,

TABLE 3: The results of bioactive compounds of the herbs with high binding affinity scores (≥9.0 kcal/mol).

Herb	Bioactive compounds	PubChem ID	Structure
	Atractylenolide III	155948	0 0
Atractylodes lancea (Thunb.) Dc.	Oroxindin	3084961	
	Hesperidin	10621	
Citrus reticulata Blanco	Naringin	442428	
Magnolia officinalis Rehd. et Wils.	Neohesperidin	442439	

Table 3: Continued.

Herb	Bioactive compounds	PubChem ID	Structure
	Acanthoside B	443024	
	Acteoside	5281800	
Agastache rugosa	Campneoside	5315651	
	Hyperin	5281643	
	Orobanchoside	6441894	

Table 3: Continued.

Herb	Bioactive compounds	PubChem ID	Structure
	Hirsutrin	5280804	
	Hyperin	5281643	
Amomum tsaoko Crevost et Lemarie	Quercetin 3-o-glucoside	5280804	
	Quercetin 3-o- rhamnopyranosyl	N/A	HO HO HO HO HO O
	Quercetin 3-o-rutinoside (synonymous: rutin)	5280805	

Table 3: Continued.

Herb	Bioactive compounds	PubChem ID	Structure
	Cosmetin	5280704	
	Hesperidin	10621	
	Luteolin 7-O-glucuronide	5280601	
	Rutin	5280805	
Ephedra sinica Stapf	Tilianine	5321954	
	Vitexin	5280441	
	Chrysoeriol 7-rutinoside	14374725	
	Coumarin-glycoside	N/A	HO HO HO HO HO HO
	6'-feruloylnodakenin	6439317	

Table 4: The chemical compounds with active result from bioassay against respiratory infectious viral activity.

Herb	Chemical compound	Virus type	Minimal concentration	Study type	Reference
Atractylodes lancea (Thunb.) Dc. Citrus reticulata Blanco	Atractylenolide III	Porcine reproductive and respiratory syndrome virus SARS-CoV-2	IC <sub>50</sub> = 99.6 μmol/L N/A	In vitro In silico	[10]
Agastache rugosa Amomum tsaoko	Hesperidin				[11, 12]
Crevost et Lemarie Ephedra sinica Stapf Agastache rugosa	Quercetin	SARS-CoV	$IC_{50} = 8.1 \pm 0.3 \mu\text{m}$	In vitro	[13]
Amomum tsaoko Crevost et Lemarie Ephedra sinica Stapf Agastache rugosa	Quercetin	Influenza A virus H1N1 A/PR/ 8/34	$EC_{50} = 43.1 \mu\text{m}$	In vitro	[14]
Amomum tsaoko Crevost et Lemarie Ephedra sinica Stapf	Quercetin	SARS-CoV	$IC_{50} = 23.8 \mu\text{m}$	In vitro	[15]
Agastache rugosa Ephedra sinica Stapf	Apigenin	Influenza A virus H1N1 A/PR/ 8/34	$IC_{50} = 31.6 \pm 0.9 \mu\text{m}$	In vitro	[16]
Agastache rugosa Ephedra sinica Stapf	Apigenin	Influenza A virus H3N2 A/ Jinan/15/90	$IC_{50} = 28.9 \pm 0.7 \mu\text{m}$	In vitro	[16]
Agastache rugosa Ephedra sinica Stapf Amomum tsaoko	Apigenin	Influenza A virus B/Jiangsu/ 10/2003	$IC_{50} = 45.7 \pm 2.3 \mu\text{m}$	In vitro	[16]
Crevost et Lemarie Ephedra sinica Stapf	Quercetin, 3-o-rutinoside (Synonymous rutin)	Influenza A virus H1N1	$IC_{50} = 34.4 \pm 5.0 \mu\text{m}$	In vitro	[14]
Amomum tsaoko Crevost et Lemarie	Hirsutrin	Influenza A virus A/swine/ OH/511445/2007 H1N1	$ED_{50} = 1.2 \mu m$	In vitro and in vivo	[17]
Ephedra sinica Stapf	Cosmetin	Influenza A virus H1N1 A/PR/ 8/34	$EC_{50} = 43.0 \mu m$	In vitro	[14]
Ephedra sinica Stapf	Vitexin	Influenza A virus H1N1 A/PR/ 8/34	$IC_{50} = 46.5 \pm 0.6 \mu\text{m}$	In vitro	[16]
Ephedra sinica Stapf	Vitexin	Influenza A virus H3N2 A/ Jinan/15/90	$IC_{50} = 45.1 \pm 1.3 \mu\text{m}$	In vitro	[16]
Ephedra sinica Stapf	Vitexin	Influenza A virus B/Jiangsu/ 10/2003	$IC_{50} = 49.6 \pm 3.1 \mu\text{m}$	In vitro	[16]
Ephedra sinica Stapf	Luteolin	Influenza A virus H1N1 A/PR/ 8/34	$IC_{50} = 33.7 \pm 0.7 \mu\text{m}$	In vitro	[16]
Ephedra sinica Stapf	Luteolin	Influenza A virus H3N2 A/ Jinan/15/90	$IC_{50} = 32.6 \pm 0.1 \mu\text{m}$	In vitro	[16]
Ephedra sinica Stapf	Luteolin	Influenza A virus B/Jiangsu/ 10/2003 Influenza A virus H1N1 A/PR/	$IC_{50} = 53.3 \pm 5.1 \mu\text{m}$	In vitro	[16]
Ephedra sinica Stapf	Herbacetin	8/34	$EC_{50} = 35.0 \mu\text{m}$	In vitro	[14]
Ephedra sinica Stapf	Kaempferol	Influenza A virus H1N1 A/PR/ 8/34	$IC_{50} = 58.6 \pm 0.6 \mu\text{m}$	In vitro	[16]
Ephedra sinica Stapf	Kaempferol	Influenza A virus H3N2 A/ Jinan/15/90	$IC_{50} = 38.1 \pm 0.3 \mu\text{m}$	In vitro	[16]
Ephedra sinica Stapf	Kaempferol	Influenza A virus B/Jiangsu/ 10/2003	$IC_{50} = 46.4 \pm 0.8 \mu\text{m}$	In vitro	[16]
Zingiber officinale Roscoe	Euxanthone	Influenza A virus H1N1	$IC_{50} = 23.54 \pm 3.68 \mu\text{m}$	In vitro	[18]
Zingiber officinale Roscoe	Euxanthone	Influenza A virus H9N2	$IC_{50} = 22.45 \pm 3.45 \mu\text{m}$	In vitro	[18]
Zingiber officinale Roscoe	Euxanthone	Influenza A virus H1N1 swine	$IC_{50} = 11.54 \pm 0.35 \mu\text{m}$	In vitro	[18]
Zingiber officinale Roscoe	Euxanthone	Influenza A virus H1N1 (H274Y)	$IC_{50} = 13.01 \pm 0.41 \mu\text{m}$	In vitro	[18]

 $EC_{50}$ : half maximal effective concentration;  $IC_{50}$ : half maximal inhibitory concentration.




FIGURE 1: The simulation model of SARS-CoV-2 spike glycoprotein and angiotensin-converting enzyme 2.




FIGURE 2: The simulation model of SARS-CoV spike glycoprotein and angiotensin-converting enzyme 2.

and have low hERG inhibition risk (namely, hERG gene inhibition by chemical substance usually associated with the occurrence of prolonged QT syndrome, used as a standardised test for toxicity screening) [5].

2.8. Structural Analysis of the Identified Chemical Agent with Angiotensin-Converting Enzyme 2. The identified chemical compound and the ACE2 target were visualised in PyMOL to facilitate identification of specific residue interactions with active binding sites on the target. The PDBQT files of the binding ligand (chemical compound) and ACE2 obtained from AutoDock Vina were used as input files in PyMOL. The binding sites were highlighted in different colours and labelled with residue names.

# 3. Results

3.1. Model of the Binding Complex of SARS-CoV-2/SARS-CoV Spike Glycoproteins and Angiotensin-Converting Enzyme 2. The predicted model of the SARS-CoV-2 spike glycoprotein and angiotensin-converting enzyme 2 illustrated the

interactions of these two proteins. Figure 1 shows the SARS-CoV-2 spike glycoprotein coloured by its 3 different chains, with green for chain A, cyan for chain B, and red for chain C. ACE2 is coloured in magenta. Figure 1 indicates that the chain B and chain C of SARS-CoV-2 spike glycoprotein both contact ACE2.

For comparison, the predicted model of the SARS-CoV spike glycoprotein and angiotensin-converting enzyme 2 illustrating the interactions of these two proteins is shown in Figure 2. The SARS-CoV spike glycoprotein is coloured by its 3 different chains, with green for chain A, cyan for chain B, and red for chain C. ACE2 is coloured in magenta. Inspection of the complex structural model shown in Figure 2 indicates that, in contrast to that of the SARS-CoV-2 spike glycoprotein, only chain C of the SARS-CoV spike glycoprotein is predicted to bind with ACE2.

3.2. Identification of the Binding Chains and Binding Site Residues of the SARS-CoV-2 Spike Glycoprotein and Angiotensin-Converting Enzyme 2. The interface result of the PDBePISA analysis for the binding complex of SARS-CoV-2

spike glycoprotein and ACE2 confirmed that both the chain B and chain C of SARS-CoV-2 spike glycoprotein form binding contacts with ACE2 (chain D). Detail information regarding the interaction between each of the relevant protein chains, interface contact areas, and estimated free energies of interactions is listed in Table 1. These results suggest that chain B and chain C of the SARS-CoV-2 spike glycoprotein contribute to the interaction with ACE2, with an estimated binding  $\Delta G$  of -11.2 kcal/mol and an estimated  $\Delta G$  of -5.3 kcal/mol, respectively.

The hydrogen bonds predicted to be formed between chain B of SARS-CoV-2 spike glycoprotein and ACE2 (chain D) showed that the main contributors to the interactions on chain B include THR333, ASN370, and ALA372. Likewise, the residues which make up binding sites on ACE2 included LYS600, SER254, and ALA614. The hydrogen bond-forming residues of chain C in SARS-CoV-2 spike glycoprotein include GLU484, GLN493, LYS417, ASN487, TYR489, GLN493, and TYR505. Likewise, the binding site residues on ACE2 which contribute to its interactions with SARS-CoV-2 chain C include ASP157, ASN159, ASP615, SER280, TYR252, and TYR613. Further detailed information regarding these key interactions is listed in Tables 5 and 6.

3.3. Identification of the Binding Chains and the Binding Site Residues of the SARS-CoV Spike Glycoprotein and Angiotensin-Converting Enzyme 2. The interface result of the PDBePISA analysis for the binding complex of the SARS-CoV spike glycoprotein and ACE2 confirmed that the chain C of SARS-CoV spike glycoprotein is the only chain which forms close contact with ACE2 (chain D), in contrast to SARS-CoV-2 in which both chains B and C form close contact. Further detailed information is listed in Table 7.

The hydrogen bond-forming residues of chain C in the SARS-CoV spike glycoprotein and ACE2 (chain D) complex showed that residues on chain C involved in binding ACE2 include ARG 426, TYR 436, ASN 473, TYR 475, THR 486, THR 487, ILE 489, TYR 484, and GLY 482. Likewise, the H-bond-forming binding site residues on ACE2 included GLN 24, GLN 42, ASP 38, TYR 41, TYR 83, GLN 325, ASN 330, and LYS 353. Further detailed information is listed in Table 8.

3.4. Comparison of the ACE2-Binding Regions of the SARS-CoV-2 and SARS-CoV Spike Glycoproteins. Comparison of the predicted binding chains and binding sites of the complexes demonstrated that SARS-CoV-2 had two chains (chain B and chain C) binding with ACE2, while in contrast, the SARS-CoV only had one chain (chain C) binding with ACE2. Examination of the specific residues involved in binding indicates that there is one common residue, at position 487, which is used by both SARS-CoV-2 and SARS-CoV spike glycoproteins to bind with ACE2.

3.5. Molecular Docking Screening of ACE2-Targeting Chemical Compounds from Designated Herbs. The chemical compounds from the herbs which satisfy the selection criteria

TABLE 5: Hydrogen bond-forming residues of chain B in SARS-CoV-2 spike glycoprotein and angiotensin-converting enzyme 2 (chain D).

##	Structure 1 (chain D)	Dist. (Å)	Structure 2 (chain B)
1	D: LYS 600[HZ2]	1.72	B: THR 333[OG1]
2	D: SER 254[O]	1.93	B: ASN 370[HD22]
3	D: ALA 614[O]	1.95	B: ALA 372[H]

Table 6: Hydrogen bond-forming residues of chain C in SARS-CoV-2 spike glycoprotein and angiotensin-converting enzyme 2 (chain D).

##	Structure 1 (chain D)	Dist. (Å)	Structure 2 (chain C)
1	D: ASP 157[H]	2.04	C: GLU 484[OE2]
2	D: ASN 159[HD22]	1.96	C: GLN 493[OE1]
3	D: ASP 615[OD1]	1.86	C: LYS 417[HZ1]
4	D: ASP 615[OD2]	1.75	C: LYS 417[HZ2]
5	D: SER 280[O]	2.05	C: ASN 487[HD22]
6	D: TYR 252[OH]	1.97	C: TYR 489[HH]
7	D: ASP 157[OD1]	2.18	C: GLN 493[HE22]
8	D: TYR 613[O]	1.91	C: TYR 505[HH]

amongst the nine herbs include the following: 11 chemical compounds from Atractylodes lancea (Thunb.) Dc. (Cangzhu), 31 chemical compounds from Citrus reticulata Blanco (Chenpi), 59 chemical compounds from Magnolia officinalis Rehd. et Wils. (Houpo), 38 chemical compounds from Agastache rugosa (Huoxiang), 30 chemical compounds from Amomum tsaoko Crevost et Lemarie (Caoguo), 204 chemical compounds from Ephedra sinica Stapf (Mahuang), 62 chemical compounds from Notopterygium franchetii H. de Boiss. (Qianghuo), 82 chemical compounds from Zingiber officinale Roscoe (Shengjiang), and 18 chemical compounds from Areca catechu L. (Binglang). Further detailed information is listed in Supplementary docking result file.

The binding affinity values for all docked compounds are presented in Supplementary docking result file. Chemical compounds which show binding affinity values greater than the cutoff value of 9 kcal/mol are atractylenolide III (9.1 kcal/ mol) and oroxindin (9.5 kcal/mol) from Atractylodes lancea (Thunb.) Dc. (Cangzhu); hesperidin (10 kcal/mol) and naringin (10.5 kcal/mol) from Citrus reticulata Blanco (Chen pi); neohesperidin (10.6 kcal/mol) from Magnolia officinalis Rehd. et Wils. (Houpo); acanthoside B (9.1 kcal/mol), acteoside (9.5 kcal/mol), campneoside (9.3 kcal/mol), hyperin (10.2 kcal/mol), and orobanchoside (10.3 kcal/mol) from Agastache rugosa (Huoxiang); hirsutrin (10.1 kcal/ mol), hyperin (10.2 kcal/mol), quercetin 3-o-glucoside (10.1 kcal/mol), quercetin 3-o-rhamnopyranosyl (9.7 kcal/ mol), and quercetin 3-o-rutinoside (10.4 kcal/mol) from Amomum tsaoko Crevost et Lemarie (Caoguo); cosmetin (9.2 kcal/mol), hesperidin (10 kcal/mol), luteolin 7-O-glucuronide (9.3 kcal/mol), rutin (10.4 kcal/mol), tilianine (9.2 kcal/mol), and vitexin (9.0 kcal/mol) from Ephedra sinica Stapf (Mahuang); and chrysoeriol 7-rutinoside (10 kcal/mol), coumarin-glycoside (9.4 kcal/mol), and 6'feruloylnodakenin (10.4 kcal/mol) from Notopterygium Chain C

Chain D (ACE2)

Chain B

Chain C

0.222

0.325

111222 , , 1 1	SECTION MICHIAGO TOURIN OF O	ino do , opino 81/coprotein unu u	ingroterioni converting cim/in	2 (6114111 2).
Structure 1	Structure 2	Interface area (A <sup>2</sup> )	ΔiG (kcal/mol)	$\Delta iG$ ( $P$ value)
Chain A	Chain B	4679.7	-46.3	0.328
Chain A	Chain C	4326.6	-38.4	0.424

TABLE 7: PDBePISA interface result of SARS-CoV spike glycoprotein and angiotensin-converting enzyme 2 (chain D).

Table 8: Hydrogen bond-forming residues of chain C in SARS-CoV spike glycoprotein and angiotensin-converting enzyme 2 (chain D).

3749.1

904.1

##	Structure 1 (chain C)	Dist. (Å)	Structure 2 (chain D)
1	C: ARG 426[NH1]	2.69	D: GLN 325[OE1]
2	C: TYR 436[OH]	2.81	D: ASP 38[OD1]
3	C: TYR 436[OH]	2.72	D: ASP 38[OD2]
4	C: ASN 473[ND2]	3.46	D: GLN 24 [O]
5	C: ASN 473[ND2]	2.40	D: TYR 83[OH]
6	C: TYR 475[OH]	3.88	D: TYR 83[OH]
7	C: THR 486[OG1]	3.39	D: TYR 41[OH]
8	C: THR 487[N]	3.89	D: TYR 41[OH]
9	C: ILE 489[N]	3.65	D: GLN 325[OE1]
10	C: THR 486[O]	3.50	D: TYR 41[OH]
11	C: TYR 484[OH]	2.99	D: GLN 42[NE2]
12	C: TYR 436[OH]	2.77	D: GLN 42[NE2]
13	C: THR 486[O]	3.22	D: ASN 330[ND2]
14	C: GLY 482[O]	3.00	D: LYS 353[NZ]

franchetii H. de Boiss. (Qianghuo). No compounds with satisfaction of the cutoff value from Zingiber officinale Roscoe (Shengjiang) and Areca catechu L. (Binglang) were identified. Table 3 demonstrates the results of chemical compounds and structures with high binding affinity scores (≥9 kcal/mol).

3.6. Text Mining Results for the Antiviral Activity of the Identified Chemical Compounds. From the findings of the in vitro, in vivo, and in silico studies, the chemical compounds with antirespiratory viral activities are apigenin, atractylenolide III, cosmetin, euxanthone, herbacetin, Hesperidin, hirsutrin, kaempferol, luteolin, quercetin, quercetin 3-orutinoside, and vitexin. The detailed information is presented in Table 4.

3.7. Pharmacokinetic Property Screening and Prediction. The chemical compound which satisfies the binding affinity and ADMET screening selection criteria is atractylenolide III from Atractylodes lancea (Thunb.) Dc. (Cangzhu) with eligible water solubility, high GI absorption, eligible druglikeness and low hERG inhibition risk. All the other chemical compounds were excluded due to unsuitable water solubility, GI absorption, druglikeness, and toxicity. Specifically, oroxindin was excluded with the reason of low GI absorption. For Amomum tsaoko Crevost et Lemarie (Caoguo), quercetin 3-o-glucoside, hirsutrin, and hyperin were excluded due to low GI absorption, violations of Lipinski's rules, and high hERG inhibition risk. Quercetin 3o-rutinoside and quercetin 3-o-rhamnopyranosyl were excluded due to low GI absorption and violations of Lipinski's rules. For Citrus reticulata Blanco (Chenpi), hesperidin,

hyperin, naringin, and orobanchoside were excluded due to low GI absorption, violations of Lipinski's rules, and high hERG inhibition risk. For Magnolia officinalis Rehd. et Wils. (Houpo), neohesperidin was excluded for the reasons of low GI absorption, violations of Lipinski's rules, and high hERG inhibition risk. For Agastache rugosa (Huoxiang), acanthoside B, acteoside, and campneoside were excluded due to low GI absorption and violations of Lipinski's rules. For Notopterygium franchetii H. de Boiss (Qianghuo), chrysoeriol 7-rutinoside was excluded due to low GI absorption, violations of Lipinski's rules, and high hERG inhibition risk. Coumarin- glycoside was excluded due to low GI absorption and medium hERG inhibition risk. 6'-Feruloylnodakenin was ruled out due to low GI absorption, violations of Lipinski's rules, and medium hERG inhibition risk. For Ephedra sinica Stapf (Mahuang), cosmetin was excluded due to low GI absorption and high hERG inhibition risk. Hesperidin and luteolin 7-O-glucuronide were excluded due to low GI absorption, violations of Lipinski's rules, and high hERG inhibition risk. Rutin was excluded due to low GI absorption and violations of Lipinski's rules. Tilianine was excluded due to low GI absorption and medium hERG inhibition risk. Vitexin was excluded due to low GI absorption and high hERG inhibition risk. Further detailed information of each identified chemical compounds' pharmacokinetic property screening and prediction is summarized in Table 9.

-41.7

-8.8

3.8. Structural Analysis of the Identified Chemical Agent with Angiotensin-Converting Enzyme 2. The molecular graphic of the docking residue is shown in Figure 3, showing the predicted interaction between ACE2 and atractylenolide III, shown in ribbon form in magenta, and atractylenolide III,

Table 9: The screening and prediction of ADME and toxicity for the identified chemical compounds with antiviral activity ( $\geq$ 7 kcal/mol) from PreADME and SwissADME.

Herb  Atractylodes lancea (Thunk.) Dc.	Chemical compound  Atractylenolide III	Water solubility  Log S (ISOL)  -2-70 Solubility  4.93e-01 mg/mt, 1.98e-03 mol/1 Class Soluble Log S (Ali) -2-71 Solubility  4.87e-01 mg/mt, 1.98e-03 mol/1 Class Soluble Log S (SILICOS-IT) -3-15 Solubility  1.78e-01 mg/mt, 1.76e-04 mol/1 Class Cabulity Class Cabulity Class Cabulity Class Cabulity Class Cabulity Class Cabulity Class Class Class	Pharmacokinetics  GI absorption High BBB permeant Yes P-gp substrate No CYP1A2 inhibitor No CYP2C19 inhibitor No CYP2C9 inhibitor No CYP2C9 inhibitor No CYP2A4 inhibitor No CYP3A4 inhibitor No CYP3A4 inhibitor No Log Kp (skin permeation)  -6.32 cm/s	Druglikeness  Lipinski Yes; 0 violation Ghose Yes Veber Yes Egan Yes Muegge Yes Bioavailability score 0.55	Toxicity  Algae at 0.0292313 Ames test mutagen Carcino Mouse negative Carcino Rat positive Daphnia at 0.0794231 hERG inhibition low risk Medaka at 0.00923153 Minnow at 0.00623542 TA100 10RL1 negative TA1535 10RL1 positive TA1535 10RL1 positive TA1535 An negative	Eligibilit Yes
Atractylodes lancea (Thunh.) Dc.	Atractylenolide III	-2.70 Solubility 4.93e -01 mg/ml: 1.98e -03 mol/l Class Soluble Log S (Ali) -2.71 Solubility 4.87e -01 mg/ml: 1.96e -03 mol/l Class Soluble Log S (SILICOS-IT) -3.15 Solubility 1.78e -01 mg/ml: 7.16e -04 mol/l Class Class	BBB permeant Yes P-gp substrate No CYP1A2 inhibitor No CYP2C9 inhibitor No CYP2C9 inhibitor No CYP2C9 inhibitor No CYP2D6 inhibitor No CYP2D6 inhibitor No CYP3A4 inhibitor No Log Kp (skin permeation)	Ghose Yes Veber Yes Egan Yes Muegge Yes	Ames test mutagen Carcino Mouse negative Carcino Rat positive Daphnia at 0.0794231 hERG inhibition low risk Medaka at 0.00923153 Minnow at 0.00563542 TA100 10RL1 negative TA105 10RL1 positive TA105 10RL1 positive	Yes
Atractylodes lancea (Thunk.) Dc.	Atractylenolide III	4.9% = -01 mg/ml. 1.9% = -03 mol/l Class Soluble 1.og S (Aii) -2.71 Solubility 4.87e = 01 mg/ml. 1.96e - 03 mol/l Class Soluble 1.og S (SILICOS-IT) -3.15 Solubility 1.78e = 01 mg/ml; 7.16e - 04 mol/l Class	BBB permeant Yes P-gp substrate No CYP1A2 inhibitor No CYP2C9 inhibitor No CYP2C9 inhibitor No CYP2C9 inhibitor No CYP2D6 inhibitor No CYP2D6 inhibitor No CYP3A4 inhibitor No Log Kp (skin permeation)	Ghose Yes Veber Yes Egan Yes Muegge Yes	Ames test mutagen Carcino Mouse negative Carcino Rat positive Daphnia at 0.0794231 hERG inhibition low risk Medaka at 0.00923153 Minnow at 0.00563542 TA100 10RL1 negative TA105 10RL1 positive TA105 10RL1 positive	Yes
Atracylodes lancea (Thunh.) Dc.	Atractylenolide III	Class Soluble Log S (Ali)2.71 Solubility 4.87e - 01 mg/ml. 1.96e - 03 mol/1 Class Solubilor Log S (SILICOS-IT)3.15 Solubility 1.78e - 01 mg/ml. 7.16e - 04 mol/1 Class	BBB permeant Yes P-gp substrate No CYP1A2 inhibitor No CYP2C9 inhibitor No CYP2C9 inhibitor No CYP2C9 inhibitor No CYP2D6 inhibitor No CYP2D6 inhibitor No CYP3A4 inhibitor No Log Kp (skin permeation)	Ghose Yes Veber Yes Egan Yes Muegge Yes	Ames test mutagen Carcino Mouse negative Carcino Rat positive Daphnia at 0.0794231 hERG inhibition low risk Medaka at 0.00923153 Minnow at 0.00563542 TA100 10RL1 negative TA105 10RL1 positive TA105 10RL1 positive	Yes
Atractylodes lancea (Thunh.) Dc.	Atractylenolide III	Soluble  Log S (Ali)  -2-711  Solubliny  4.87e - 01 mg/mt   1.96e - 03 mol/l  Class  Soluble  Log S (SILICOS-IT)  -3-15  Solubliny  1.78e - 01 mg/mt   7.16e - 04 mol/l  Class	BBB permeant Yes P-gp substrate No CYP1A2 inhibitor No CYP2C9 inhibitor No CYP2C9 inhibitor No CYP2C9 inhibitor No CYP2D6 inhibitor No CYP2D6 inhibitor No CYP3A4 inhibitor No Log Kp (skin permeation)	Ghose Yes Veber Yes Egan Yes Muegge Yes	Carcino Mouse negative Carcino Rat positive Daphnia at 0.0794231 hERG inhibition low risk Medaka at 0.00923153 Minnow at 0.00563542 TA100 lORLI negative TA1535 lORLI positive TA1535 lORLI positive	Yes
Atractylodes lancea (Thunh.) Dc.	Atractylenolide III	$-2.71$ Solubility 4.87 $\epsilon$ = 01 mg/ml, 1.96 $\epsilon$ = 03 mol/1 Class Soluble Log 5 (SILICOS-IT) -3.15 Solubility 1.78 $\epsilon$ = 01 mg/ml, 7.16 $\epsilon$ = 04 mol/1 Class	CYP1A2 inhibitor No CYP2C19 inhibitor No CYP2C9 inhibitor No CYP2D6 inhibitor No CYP3A4 inhibitor No Log Kp (skin permeation)	Ghose Yes Veber Yes Egan Yes Muegge Yes	Daphnia at 0.0794231 hERG inhibition low risk Medaka at 0.00923153 Minnow at 0.00563542 TA100 10RLI negative TA103 NA negative TA1535 10RLI positive	Yes
Atractylodes lancea (Thunh.) Dc.	Atractylenolide III	Solubility 4.87e - 01 mg/ml; 1.96e - 03 mol/l Class Solubiles Log S (SILICOS-IT) -3.15 Solubility 1.78e - 01 mg/ml; 7.16e - 04 mol/l Class	CYP2C19 inhibitor No CYP2C9 inhibitor No CYP2D6 inhibitor No CYP3A4 inhibitor No Log Kp (skin permeation)	Veber Yes Egan Yes Muegge Yes	hERG inhibition low risk Medaka at 0.00923153 Minnow at 0.00563542 TA100 10RLI negative TA100 NA negative TA1535 10RLI positive	Yes
Atractylodes lancea (Thunh.) Dc.	Atractylenolide III	4.87e – 01 mg/ml. 1.96e – 03 mol/l Class Soluble Log 5 (SILICOS-IT) –3-15 Solubility 1.78e – 01 mg/ml. 7.16e – 04 mol/l Class	CYP2C9 inhibitor No CYP2D6 inhibitor No CYP3A4 inhibitor No Log Kp (skin permeation)	Egan Yes Muegge Yes	Medaka at 0.00923153 Minnow at 0.00563542 TA100 10RLI negative TA100 NA negative TA1535 10RLI positive	Yes
		Class Soluble Log S (SILICOS-IT) -3.15 Solubility 1.78e - 01 mg/ml; 7.16e - 04 mol/1 Class	CYP2D6 inhibitor No CYP3A4 inhibitor No Log Kp (skin permeation)	Muegge Yes	Minnow at 0.00563542 TA100 10RLI negative TA100 NA negative TA1535 10RLI positive	
		Log S (SILICOS-IT)  -3.15  Solubility  1.78e – 01 mg/ml; 7.16e – 04 mol/1  Class	Log Kp (skin permeation)	Bioavailability score 0.55	TA100 NA negative TA1535 10RLI positive	
		−3.15 Solubility 1.78e − 01 mg/ml; 7.16e − 04 mol/l Class			TA1535 10RLI positive	
		Solubility 1.78e – 01 mg/ml; 7.16e – 04 mol/l Class				
		Class				
		Soluble				
		Log S (ESOL)				
		-3.04				
		Solubility 4.23e – 01 mg/ml; 9.10e – 04 mol/l				
		Class	GI absorption Low	Lipinski	Algae at 0.0220269 Ames test non-mutagen	
		Soluble	BBB permeant No	No; 2 violations: NorO > 10, NHorOH > 5 Ghose	Carcino Mouse negative	
		Log S (Ali) -4.35	P-gp substrate No CYP1A2 inhibitor No	No; 1 violation: WLOGP < -0.4	Carcino Rat negative Daphnia at 1.47843	
		Solubility	CYP2C19 inhibitor No	Veber	hERG inhibition high risk	
	Hirsutrin	2.10e – 02 mg/ml; 4.51e – 05 mol/l	CYP2C9 inhibitor No	No; 1 violation: TPSA > 140 Egan	Medaka at 3.73921	No
		Class	CYP2D6 inhibitor No	No; 1 violation: TPSA > 131.6	Minnow at 1.38214	
		Moderately soluble Log S (SILICOS-IT)	CYP3A4 inhibitor No Log Kp (skin permeation)	Muegge	TA100 10RLI negative TA100 NA negative	
		-1.51	-8.88 cm/s	No; 3 violations: TPSA > 150, H-acc > 10, H-don > 5	TA153510RLI negative	
		Solubility		Bioavailability score 0.17	TA1535 NA negative	
		1.43e + 01 mg/ml; 3.08e - 02 mol/l				
		Class Soluble				
		Log S (ESOL) -3.16			Algae at 0.0378136	
		Solubility 2.11e - 01 mg/ml; 6.98e - 04 mol/l	GI absorption High		Ames test mutagen	
		Class Soluble	BBB permeant No	Lipinski Yes; 0 violation	Carcino Mouse negative Carcino Rat positive	
		Log S (Ali) -3.91	P-gp substrate No	Lipinski Yes; U violation Ghose Yes	Daphnia at 0.214345	
	Quercetin	Solubility 3.74e - 02 mg/ml; 1.24e - 04 mol/l	CYP1A2 inhibitor Yes CYP2C19 inhibitor No	Veber Yes	hERG inhibition medium risk	No
		Class Soluble	CYP2C9 inhibitor No	Egan Yes	Medaka at 0.0778806 Minnow at 0.0335026	
		Soluble Log S (SILICOS-IT) =3.24	CYP2D6 inhibitor Yes	Muegge Yes Bioavailability score 0.55	TA100 10RLI negative	
		Solubility 1.73e - 01 mg/ml; 5.73e - 04 mol/l	CYP3A4 inhibitor Yes Log Kp (skin permeation) -7.05 cm/s	7,	TA100 NA positive	
		Class	Log Kp (skin permeation) -7.05 cm/s		TA1535 10RLI negative	
		Soluble Log S (ESOL)			TA1535 NA negative	
		-3.04				
Amomum tsaoko Crevost et Lemarie		Solubility				
		4.23e – 01 mg/ml; 9.10e – 04 mol/l Class	CI sharming I am	Lipinski	Algae at 0.0220269	
		Soluble	GI absorption Low BBB permeant No	No; 2 violations: NorO > 10, NHorOH > 5	Ames test non-mutagen Carcino Mouse negative	
		Log S (Ali)	P-gp substrate No	Ghose	Carcino Rat negative	
		4.25		No. 1 violation, WI OCP < 0.4		
Quercet		-4.35	CYP1A2 inhibitor No	No; 1 violation: WLOGP < -0.4 Veber	Daphnia at 1.47843	
	etin, 3-o-glucoside (synonymous hirsutrin)	Solubility	CYP2C19 inhibitor No		hERG inhibition high risk	No
	etin, 3-o-glucoside (synonymous hirsutrin)		CYP2C19 inhibitor No CYP2C9 inhibitor No	Veber No; 1 violation: TPSA > 140 Egan		No
	etin, 3-o-glucoside (synonymous hirsutrin)	Solubility 2.10e – 02 mg/ml; 4.51e – 05 mol/l Class Moderately soluble	CYP2C19 inhibitor No CYP2C9 inhibitor No CYP2D6 inhibitor No CYP3A4 inhibitor No	Veber No; 1 violation: TPSA > 140 Egan No; 1 violation: TPSA > 131.6	hERG inhibition high risk Medaka at 3.73921 Minnow at 1.38214 TA100 10RLI negative	No
	etin, 3-o-glucoside (synonymous hirsutrin)	Solubility $2.10e - 02 \text{ mg/ml}$ : $4.51e - 05 \text{ mol/l}$ Class Moderately soluble Log S (SILICOS-IT)	CYP2C19 inhibitor No CYP2C9 inhibitor No CYP2D6 inhibitor No CYP3A4 inhibitor No Log Kp (skin permeation)	Veber No; 1 violation: TPSA > 140 Egan	hERG inhibition high risk Medaka at 3.73921 Minnow at 1.38214 TA100 10RLI negative TA100 NA negative	No
	etin, 3-o-glucoside (synonymous hirsutrin)	Solubility  2.10e – 02 mg/m!; 4.51e – 05 mol/1 Class  Moderately soluble Log S (SILICOS-IT) –1.51	CYP2C19 inhibitor No CYP2C9 inhibitor No CYP2D6 inhibitor No CYP3A4 inhibitor No	Veber No: 1 violation: TPSA > 140 Egan No: 1 violation: TPSA > 131.6 Muegge	hERG inhibition high risk Medaka at 3.73921 Minnow at 1.38214 TA100 10RLI negative TA100 NA negative TA1535 10RLI negative	No
	rtin, 3-o-glucoside (synonymous hirsutrin)	Solubility $2.10e - 02 \text{ mg/ml}$ : $4.51e - 05 \text{ mol/l}$ Class Moderately soluble Log S (SILICOS-IT)	CYP2C19 inhibitor No CYP2C9 inhibitor No CYP2D6 inhibitor No CYP3A4 inhibitor No Log Kp (skin permeation)	Veber No; 1 violation: TPSA > 140 Egan No; 1 violation: TPSA > 131.6 Muegge No; 3 violations: TPSA > 150, H-acc > 10, H-don > 5	hERG inhibition high risk Medaka at 3.73921 Minnow at 1.38214 TA100 10RLI negative TA100 NA negative	No
	rtin, 3-o-glucoside (synonymous hirsutrin)	Solubility 2.10e-02 mg/ml. 4.51e-05 mol/l Class Moderately soluble Log S (SHLCOS-TT) -1.51 Solubility 1.43e+01 mg/ml. 3.08e-02 mol/l Class	CYP2C19 inhibitor No CYP2C9 inhibitor No CYP2D6 inhibitor No CYP3A4 inhibitor No Log Kp (skin permeation)	Veber No; 1 violation: TPSA > 140 Egan No; 1 violation: TPSA > 131.6 Muegge No; 3 violations: TPSA > 150, H-acc > 10, H-don > 5	hERG inhibition high risk Medaka at 3.73921 Minnow at 1.38214 TA100 10RLI negative TA100 NA negative TA1535 10RLI negative	No
	etin, 3-o-glucoside (synonymous hirsutrin)	Solubility 2.10e - 02 mg/ml, 4.51e - 05 mol/l Class Moderately soluble Log S (SILICOS-IT) -1.51 Solubility 1.43e + 01 mg/ml, 3.08e - 02 mol/l Class Soluble	CYP2C19 inhibitor No CYP2C9 inhibitor No CYP2D6 inhibitor No CYP3A4 inhibitor No Log Kp (skin permeation)	Veber No; 1 violation: TPSA > 140 Egan No; 1 violation: TPSA > 131.6 Muegge No; 3 violations: TPSA > 150, H-acc > 10, H-don > 5	hERG inhibition high risk Medaka at 3.73921 Minnow at 1.38214 TA100 10RLI negative TA100 NA negative TA1535 10RLI negative	No
	ctin, 3-o-glucoside (synonymous hirsutrin)	Solubility 2.10e - 02 mg/ml. 4.51e - 05 mol/l Class Moderately soluble Log S (SILICOS-IT) -1.51 Solubility 1.43e + 01 mg/ml. 3.08e - 02 mol/l Class Soluble Log S (ESOL) -3.30	CYP2C19 inhibitor No CYP2C9 inhibitor No CYP2D6 inhibitor No CYP3A4 inhibitor No Log Kp (skin permeation)	Veber No; 1 violation: TPSA > 140 Egan No; 1 violation: TPSA > 131.6 Muegge No; 3 violations: TPSA > 150, H-acc > 10, H-don > 5	hERG inhibition high risk Medaka at 3.73921 Minnow at 1.38214 TA100 10RLI negative TA100 NA negative TA1535 10RLI negative	No
	etin, 3-o-glucoside (synonymous hirsutrin)	Solubility 2.10e - 22 mg/mt, 4.51e - 05 mol/l Class Moderately soluble Log S (SILCOS-IT) -1.51 Solubility 1.43e + 01 mg/mt, 3.08e - 02 mol/l Class Soluble Log S (ESOL) -3.30 Solubility	CYP2C19 inhibitor No CYP2C9 inhibitor No CYP2D6 inhibitor No CYP3A4 inhibitor No Log Kp (skin permeation)	Veber No; 1 violation: TPSA > 140 Egan No; 1 violation: TPSA > 131.6 Muegge No; 3 violations: TPSA > 150, H-acc > 10, H-don > 5	hRRG inhibition high risk Medaka at 3-79-91 Minnow at 1.38214 TA100 IORLI negative TA100 NA negative TA1535 10RLI negative TA1535 NA negative	No
	etin, 3-o-glucoside (synonymous hirsutrin)	Solubility 2.10e-02 mg/ml. 4.51e-05 mol/l Class Moderately soluble Log S (SILICOS-TT) -1.51 Solubility 1.43e+01 mg/ml. 3.08e-02 mol/l Class Soluble Log S (ESOL) -3.30 3.08e-01 mg/ml. 5.05e-04 mol/l	CYP2C19 inhibitor No CYP2C5 inhibitor No CYP2D6 inhibitor No CYP3A4 inhibitor No CYP3A4 inhibitor No Log Kp (skin permeation) -8.88 cm/s	Veber No; 1 volation: TPSA > 140 Egan No; 1 volation: TPSA > 131.6 Muegge No; 3 violations: TPSA > 150, H-acc > 10, H-don > 5 Bioavailability score 0.17 Lipinski	hRRG inhibition high risk Medaka at 3-73921 Minnow at 1.38214 TA100 10RL1 negative TA100 A negative TA1053 10RL1 negative TA1535 10RL1 negative TA1535 NA negative	No
	etin, 3-o-glucoside (synonymous hirsutrin)	Solubility 2.10e - 22 mg/mt, 4.51e - 05 mol/l Class Moderately soluble Log S (SILCOS-IT) -1.51 Solubility 1.43e + 01 mg/mt, 3.08e - 02 mol/l Class Soluble Log S (ESOL) -3.30 Solubility	CYP2C19 inhibitor No CYP2C9 inhibitor No CYP2D6 inhibitor No CYP3A4 inhibitor No Log Kp (skin permeation)	Veber No; 1 violation: TPSA>140 Egan No; 1 violation: TPSA>131.6 Musgee No; 3 violation: TPSA>150, H-acc>10, H-don>5 Bioavailability score 0.17 Lipinski No; 3 violation: MV>500, NorO>10, NHorOH>5	hRRG inhibition high risk Medaka at 3-79-91 Minnow at 1.38214 TA100 IORLI negative TA100 NA negative TA1535 10RLI negative TA1535 NA negative	No
	etin, 3-o-glucoside (synonymous hirsutrin)	Solubility 2.10e - 0.2 mg/ml. 4.51e - 0.5 mol/l Class Moderately soluble Log S (SILICOS-IT) -1.51 Solubility 1.43e + 01 mg/ml. 3.08e - 0.2 mol/l Class Soluble Log S (ESOL) -3.30 3.08e - 0.1 mg/ml. 3.05e - 0.4 mol/l Class Soluble Log S (Ali)	CYP2C19 inhibitor No CYP2D6 inhibitor No CYP2D6 inhibitor No CYP3A6 inhibitor No Log Kp (skin permeation)  -8.88 cm/s  GI absorption Low BBB permeant No P-gp substrate Yes	Veber No; 1volation: TPSA > 140 Egan No; 1volation: TPSA > 131.6 Musegge No; 3 violations: TPSA > 150, H-acc > 10, H-don > 5 Bioavailability score 0.17 Lipinski No; 3 violations: MW > 500, NorO > 10, NHorOH > 5 Good Parkers of the State of	hRRG inhibition high risk Medaka at 3-7921 Minnow at 1.82214 TA100 IORLI negative TA100 NA negative TA155 IORLI negative TA155 NA negative TA1555 NA negative Algae at 0.0069585 Ames test non-mutagen Carcino Mouse negative Carcino Mouse negative Carcino Mouse negative	No
		Solubility 2.10e-02 mg/ml, 4.51e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -1.51 Solubility 1.43e+01 mg/ml, 3.08e-02 mol/l Class Soluble Log S (ESOL) -3.30 Solubility 3.08e-01 mg/ml, 5.05e-04 mol/l Class Soluble Log S (Ali) -4.87	CYP2C19 inhibitor No CYP2C9 inhibitor No CYP2D6 inhibitor No CYP3A4 inhibitor No CYP3A4 inhibitor No Log Kp (skin permeatton)  -8.88 cm/s  GI absorption Low BBB permeant No P-gp substrate Ves CYP1A2 inhibitor No	Veber No; 1 violation: TPSA > 140 Egan No; 1 violation: TPSA > 131.6 Mugge No; 3 violations: TPSA > 150, H-acc > 10, H-don > 5 Bioavailability score 0.17  Lipinski No; 3 violations: MW > 500, NorO > 10, NHorOH > 5 Ghose No; 4 violations: MW > 480, WLOGP < -0.4, MR > 130, #atoms > 70 Veber	hRRG inhibition high risk Medaka at 3-78921 Minnow at 1.38214 TA100 10RL1 negative TA100 NA negative TA1535 10RL1 negative TA1535 NA negative Algae at 0.0069585 Ames test non-mutagen Carcino Mouse negative Carcino Rat negative Daphnia at 2.52355	
	Quercetin, 3-o-rutinoside	Solubility 2.10e-02 mg/ml. 4.51e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -1.51 Solubility 1.43e-01 mg/ml. 3.08e-02 mol/l Class Soluble Log S (ESIOL) -3.30 3.08e-01 mg/ml. 5.05e-04 mol/l Class Solubility 3.08e-01 mg/ml. 5.05e-04 mol/l Class Soluble Log S (Ail) -4.87 Solubility	CYP2C19 inhibitor No CYP2D6 inhibitor No CYP2D6 inhibitor No CYP3A6 inhibitor No Log Kp (skin permeation)  -8.88 cm/s  GI absorption Low BBB permeant No P-gp substrate Yes	Vober No; 1 violation: TPSA > 140 Egan No; 1 violation: TPSA > 131.6 Muegge No; 3 violation: TPSA > 150, H-acc > 10, H-don > 5 Bioavailability score 0.17  Lipinski No; 3 violations: MW > 500, NorO > 10, NhorOH > 5 Ghose No; 4 violations: MW > 480, WLOGF ~ 0.4, MR > 130, #atoms > 70 Vober No; 1 violation: TPSA > 140	hRRG inhibition high risk Medaka at 3-7921 Minnow at 1.82214 TA100 IORLI negative TA100 NA negative TA155 IORLI negative TA155 NA negative TA1555 NA negative Algae at 0.0069585 Ames test non-mutagen Carcino Mouse negative Carcino Mouse negative Carcino Mouse negative	No No
		Solubility 2.10e - 02 mg/mt. 4.51e - 05 mol/l Class Moderately soluble Log S (SHLCOS-TT) -1.51 Solubility 1.43e + 01 mg/mt. 3.08e - 02 mol/l Class Solubile Log S (ESOL) -3.30 Solubility 3.08e - 01 mg/mt. 5.05e - 04 mol/l Class Solubile Log S (Ali) -4.87 Solubility 8.30e - 03 mg/mt. 1.56e - 05 mol/l Class Colubility Class	CYP2CI9 inhibitor No CYP2Os inhibitor No CYP2Os inhibitor No CYP3A4 inhibitor No Log Ky (skin permention)  -8.88 cm/s  GI absorption Low BBB permeant No P-gp substrate Yes CYP1A2 inhibitor No CYP2CI9 inhibitor No	Veber No; 1 violation: TPSA>140 Egan No; 1 violation: TPSA>131.6 Mugge No; 3 violations: TPSA>150, H-acc>10, H-don>5 Bioavailability score 0.17  Lipinski No; 3 violations: MW>500, NorO>10, NHorOH>5 Ghose No; 4 violations: MW>480, WLOGP<-0.4, MR>130, #atoms>70 Veber No; 1 violation: TPSA>140 Egan	hRRG inhibition high risk Medaka at 3-73921 Minnow at 1.38214 TA100 10RL1 negative TA100 A negative TA1035 10RL1 negative TA1535 10RL1 negative TA1535 NA negative Algae at 0.0069585 Ames test non-mutagen Carcino Mouse negative Carcino Rat negative Daphnia at 2.55255 hERG inhibition ambiguous Medaka at 12.3433 Minnow at 5-4421	
	Quercetin, 3-o-rutinoside	Solubility 2.10e - 0.2 mg/mt. 4.51e - 0.5 mol/l Class Moderately soluble Log S (SILICOS-IT) -1.51 Solubility 1.43e + 0.1 mg/mt. 3.08e - 0.2 mol/l Class Soluble Log S (ESOL) -3.30 Solubility 3.08e - 0.1 mg/mt. 3.05e - 0.4 mol/l Class Soluble Log S (Ali) -4.87 Soluble Log S (Ali) -4.87 Solublity 8.30e - 0.3 mg/mt. 1.56e - 0.5 mol/l Class Moderately soluble	CYP2C19 inhibitor No CYP2C5 inhibitor No CYP2D6 inhibitor No CYP3A4 inhibitor No CYP3A4 inhibitor No Log Kp (skin permeation)  -8.88 cm/s  GI absorption Low BBB permeant No P.gp substrate Yes CYP1A2 inhibitor No CYP2C19 inhibitor No CYP2C19 inhibitor No CYP2C16 inhibitor No CYP2D6 inhibitor No CYP2D6 inhibitor No CYP2D6 inhibitor No CYP2D6 inhibitor No	Veber No; 1 violation: TPSA > 140 Egan No; 1 violation: TPSA > 131.6 Mugge No; 3 violations: TPSA > 150, H-acc > 10, H-don > 5 Bioavailability score 0.17  Lipinski No; 3 violations: MW > 500, NorO > 10, NHorOH > 5 Ghose No; 4 violations: MW > 480, WLOGP < −0.4, MR > 130, #atoms > 70 Veber No; 1 violation: TPSA > 140 Egan No; 1 violation: TPSA > 131.6 Mugge	hRRG inhibition high risk Medaka at 3-78921 Minnow at 1.38214 TA100 INAL negative TA100 NA negative TA1535 IORLI negative TA1535 NA negative TA1535 NA negative Algae at 0.0069585 Ames test non-mutagen Carcino Mouse negative Carcino Rat negative Daphnia at 2.5225 hERG inhibition ambiguous Medaka at 12-3433 Minnow at 5.4421 TA100 IORLI negative	
	Quercetin, 3-o-rutinoside	Solubility 2.10e - 02 mg/mt. 4.51e - 05 mol/l Class Moderately soluble Log S (SHLCOS-TT) -1.51 Solubility 1.43e + 01 mg/mt. 3.08e - 02 mol/l Class Solubile Log S (ESOL) -3.30 Solubility 3.08e - 01 mg/mt. 5.05e - 04 mol/l Class Solubile Log S (Ali) -4.87 Solubility 8.30e - 03 mg/mt. 1.56e - 05 mol/l Class Colubility Class	CYP2CI9 inhibitor No CYP2Os inhibitor No CYP2Os inhibitor No CYP3A4 inhibitor No Log Ky (skin permention)  -8.88 cm/s  GI absorption Low BBB permeant No P-gp substrate Yes CYP1A2 inhibitor No CYP2CI9 inhibitor No	Veber No; 1 violation: TPSA > 140 Egan No; 1 violation: TPSA > 131.6 Muegge No; 3 violations: TPSA > 150, H-acc > 10, H-don > 5 Bioavailability score 0.17  Lipinski No; 3 violations: MW > 500, NorO > 10, NHorOH > 5 Chose No; 4 violations: MW > 480, WLOGP < -0.4, MR > 130, #atoms > 70 Veber No; 1 violation: TPSA > 140 Egan No; 1 violation: TPSA > 131.6 Muegge No; 4 violations: MW > 600, TPSA > 131.6 Muegge No; 4 violations: MW > 600, TFSA > 131.6 Muegge No; 4 violations: MW > 600, TFSA > 131.6 Muegge	hRRG inhibition high risk Medaka at 3-73921 Minnow at 1.38214 TA100 10RL1 negative TA100 A negative TA1035 10RL1 negative TA1535 10RL1 negative TA1535 NA negative Algae at 0.0069585 Ames test non-mutagen Carcino Mouse negative Carcino Rat negative Daphnia at 2.55255 hERG inhibition ambiguous Medaka at 12.3433 Minnow at 5-4421	
	Quercetin, 3-o-rutinoside	Solubility 2.10e- 22 mg/ml. 4.51e- 0.5 mol/l Class Moderately soluble Log S (SILICOS-TT) -1.51 Solubility 1.43e+ 01 mg/ml. 3.08e- 0.2 mol/l Class Soluble Log S (ESOL) -3.30 Solubility 3.08e- 01 mg/ml. 5.05e- 0.4 mol/l Class Soluble Log S (Ali) -4.87 Solubility 8.30e- 03 mg/ml. 1.36e- 0.5 mol/l Class Moderately soluble Log S (SILICOS-TT) -0.29 Solubility	CYP2C19 inhibitor No CYP2C9 inhibitor No CYP2D6 inhibitor No CYP3A4 inhibitor No CYP3A4 inhibitor No Log Kp (skin permeation)  -8.88 cm/s  GI absorption Low BBB permeant No P-gp substrate Ves CYP1A2 inhibitor No CYP2C19 inhibitor No CYP2C9 inhibitor No CYP2C9 inhibitor No CYP2C4 inhibitor No CYP2A4 inhibitor No CYP3A4 inhibitor No CYP3A4 inhibitor No CYP3A4 inhibitor No CYP3A4 inhibitor No	Veber No; 1 violation: TPSA > 140 Egan No; 1 violation: TPSA > 131.6 Mugge No; 3 violations: TPSA > 150, H-acc > 10, H-don > 5 Bioavailability score 0.17  Lipinski No; 3 violations: MW > 500, NorO > 10, NHorOH > 5 Ghose No; 4 violations: MW > 480, WLOGP < −0.4, MR > 130, #atoms > 70 Veber No; 1 violation: TPSA > 140 Egan No; 1 violation: TPSA > 131.6 Mugge	hRRG inhibition high risk Medaka at 3-7921 Minnow at 1.8214 TA100 IORLI negative TA100 NA negative TA155 IORLI negative TA155 IORLI negative TA1555 NA negative TA1555 NA negative TA1555 NA negative Carcino Mouse negative Carcino Mouse negative Carcino Mouse negative Daphnia at 2.5525 LERG inhibition ambiguous Medaka at 12.3433 Minnow at 5.4421 TA100 IORLI negative TA100 N. negative	
	Quercetin, 3-o-rutinoside	Solubility 2.10e - 22 mg/ml. 4.51e - 05 mol/l Class  Moderately soluble Log S (SILICOS-IT) -1-51 Solubility 1.43e+01 mg/ml. 3.08e - 02 mol/l Class Solubile Log S (ESOL) -3-30 Solubility 3.08e - 01 mg/ml. 5.05e - 04 mol/l Class Solubile Log S (Ali) -4.87 Solubility 8.30e - 03 mg/ml. 1.36e - 05 mol/l Class Moderately soluble Log S (Ali) -4.87 Solubility 8.30e - 03 mg/ml. 1.36e - 05 mol/l Class Moderately soluble Log S (SILICOS-IT) -0.29 Solubility 3.15e+02 mg/ml. 5.15e-01 mol/l	CYP2C19 inhibitor No CYP2C9 inhibitor No CYP2D6 inhibitor No CYP3A4 inhibitor No CYP3A4 inhibitor No Log Kp (skin permeation)  -8.88 cm/s  GI absorption Low BBB permeant No P-gp substrate Ves CYP1A2 inhibitor No CYP2C19 inhibitor No CYP2C9 inhibitor No CYP2C9 inhibitor No CYP2C4 inhibitor No CYP2A4 inhibitor No CYP3A4 inhibitor No CYP3A4 inhibitor No CYP3A4 inhibitor No CYP3A4 inhibitor No	Veber No; 1 violation: TPSA > 140 Egan No; 1 violation: TPSA > 131.6 Muegge No; 3 violations: TPSA > 150, H-acc > 10, H-don > 5 Bioavailability score 0.17  Lipinski No; 3 violations: MW > 500, NorO > 10, NHorOH > 5 Chose No; 4 violations: MW > 480, WLOGP < -0.4, MR > 130, #atoms > 70 Veber No; 1 violation: TPSA > 140 Egan No; 1 violation: TPSA > 131.6 Muegge No; 4 violations: MW > 600, TPSA > 131.6 Muegge No; 4 violations: MW > 600, TFSA > 131.6 Muegge No; 4 violations: MW > 600, TFSA > 131.6 Muegge	hERG inhibition high risk Medaka at 3-78921 Minnow at 1.38214 TA100 IORLI negative TA105 NGLI negative TA1535 IORLI negative TA1535 NA negative Daphnia at 2.5925 hERG inhibition ambiguous Medaka at 12-3433 Minnow at 5.4421 TA100 IORLI negative TA100 NA negative TA1535 IORLI negative TA1555 IORLI negative TA1551 IORLI negative TA1555 IORLI negative	
	Quercetin, 3-o-rutinoside	Solubility 2.10e- 22 mg/ml. 4.51e- 0.5 mol/l Class Moderately soluble Log S (SILICOS-TT) -1.51 Solubility 1.43e+ 01 mg/ml. 3.08e- 0.2 mol/l Class Soluble Log S (ESOL) -3.30 Solubility 3.08e- 01 mg/ml. 5.05e- 0.4 mol/l Class Soluble Log S (Ali) -4.87 Solubility 8.30e- 03 mg/ml. 1.36e- 0.5 mol/l Class Moderately soluble Log S (SILICOS-TT) -0.29 Solubility	CYP2C19 inhibitor No CYP2C9 inhibitor No CYP2D6 inhibitor No CYP3A4 inhibitor No CYP3A4 inhibitor No Log Kp (skin permeation)  -8.88 cm/s  GI absorption Low BBB permeant No P-gp substrate Ves CYP1A2 inhibitor No CYP2C19 inhibitor No CYP2C9 inhibitor No CYP2C9 inhibitor No CYP2C4 inhibitor No CYP2A4 inhibitor No CYP3A4 inhibitor No CYP3A4 inhibitor No CYP3A4 inhibitor No CYP3A4 inhibitor No	Veber No; 1 violation: TPSA > 140 Egan No; 1 violation: TPSA > 131.6 Muegge No; 3 violations: TPSA > 150, H-acc > 10, H-don > 5 Bioavailability score 0.17  Lipinski No; 3 violations: MW > 500, NorO > 10, NHorOH > 5 Chose No; 4 violations: MW > 480, WLOGP < -0.4, MR > 130, #atoms > 70 Veber No; 1 violation: TPSA > 140 Egan No; 1 violation: TPSA > 131.6 Muegge No; 4 violations: MW > 600, TPSA > 131.6 Muegge No; 4 violations: MW > 600, TFSA > 131.6 Muegge No; 4 violations: MW > 600, TFSA > 131.6 Muegge	hERG inhibition high risk Medaka at 3-78921 Minnow at 1.38214 TA100 IORLI negative TA105 NGLI negative TA1535 IORLI negative TA1535 NA negative Daphnia at 2.5925 hERG inhibition ambiguous Medaka at 12-3433 Minnow at 5.4421 TA100 IORLI negative TA100 NA negative TA1535 IORLI negative TA1555 IORLI negative TA1551 IORLI negative TA1555 IORLI negative	
	Quercetin, 3-o-rutinoside	Solubility 2.10e-02 mg/ml, 4.51e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -1.51 Solubility 1.43e+01 mg/ml, 3.08e-02 mol/l Class Soluble Log S (ESOL) -3.30 Solubility 3.08e-01 mg/ml, 5.05e-04 mol/l Class Soluble Log S (Ali) -4.87 Solubility 3.08e-03 mg/ml, 1.36e-05 mol/l Class Moderately solubility 8.30e-03 mg/ml, 1.36e-05 mol/l Class Moderately solubility 3.15e+02 mg/ml, 5.15f-01 mol/l Class Colubility 3.15e+02 mg/ml, 5.15f-01 mol/l Class	CYP2C19 inhibitor No CYP2C9 inhibitor No CYP2D6 inhibitor No CYP3A4 inhibitor No CYP3A4 inhibitor No Log Kp (skin permeation)  -8.88 cm/s  GI absorption Low BBB permeant No P-gp substrate Ves CYP1A2 inhibitor No CYP2C19 inhibitor No CYP2C9 inhibitor No CYP2C9 inhibitor No CYP2C4 inhibitor No CYP2A4 inhibitor No CYP3A4 inhibitor No CYP3A4 inhibitor No CYP3A4 inhibitor No CYP3A4 inhibitor No	Veber No; 1 violation: TPSA > 140 Egan No; 1 violation: TPSA > 131.6 Muegge No; 3 violations: TPSA > 150, H-acc > 10, H-don > 5 Bioavailability score 0.17  Lipinski No; 3 violations: MW > 500, NorO > 10, NHorOH > 5 Chose No; 4 violations: MW > 480, WLOGP < -0.4, MR > 130, #atoms > 70 Veber No; 1 violation: TPSA > 140 Egan No; 1 violation: TPSA > 131.6 Muegge No; 4 violations: MW > 600, TPSA > 131.6 Muegge No; 4 violations: MW > 600, TFSA > 131.6 Muegge No; 4 violations: MW > 600, TFSA > 131.6 Muegge	hRRG inhibition high risk Medaka at 3.7921 Minnow at 1.38214 TA100 10RLI negative TA100 NA negative TA1535 10RLI negative TA1535 NA negative TA1535 NA negative Algae at 0.0669585 Anges test non-mutagen Carcino Mouse negative Daphnia at 2.52255 hERG inhibition ambiguous Medaka at 12.5433 Minnow at 5.4421 TA100 10RLI negative TA1535 10RLI negative TA1535 NA negative	
	Quercetin, 3-o-rutinoside	Solubility 2.10e-02 mg/ml, 4.51e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -1.51 Solubility 1.43e+01 mg/ml, 3.08e-02 mol/l Class Solubile Log S (ESOL) -3.30 Solubility 3.08e-01 mg/ml, 5.05e-04 mol/l Class Solubile Log S (Ali) -4.87 Solubility 8.30e-03 mg/ml, 1.36e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -0.29 Solubility 3.07e-02 mg/ml, 5.15e-01 mol/l Class Solubility 3.15e+02 mg/ml, 5.15e-01 mol/l Class	CYP2C19 inhibitor No CYP2C9 inhibitor No CYP2D6 inhibitor No CYP3A4 inhibitor No CYP3A4 inhibitor No Log Kp (skin permeation)  -8.88 cm/s  GI absorption Low BBB permeant No P-gp substrate Ves CYP1A2 inhibitor No CYP2C19 inhibitor No CYP2C9 inhibitor No CYP2C9 inhibitor No CYP2C4 inhibitor No CYP2A4 inhibitor No CYP3A4 inhibitor No CYP3A4 inhibitor No CYP3A4 inhibitor No CYP3A4 inhibitor No	Veber No; 1 violation: TPSA > 140 Egan No; 1 violation: TPSA > 131.6 Muegge No; 3 violations: TPSA > 150, H-acc > 10, H-don > 5 Bioavailability score 0.17  Lipinski No; 3 violations: MW > 500, NorO > 10, NHorOH > 5 Chose No; 4 violations: MW > 480, WLOGP < -0.4, MR > 130, #atoms > 70 Veber No; 1 violation: TPSA > 140 Egan No; 1 violation: TPSA > 131.6 Muegge No; 4 violations: MW > 600, TPSA > 131.6 Muegge No; 4 violations: MW > 600, TFSA > 131.6 Muegge No; 4 violations: MW > 600, TFSA > 131.6 Muegge	hRRG inhibition high risk Medaka at 3-7921 Minnow at 1.38214 TA100 IORLI negative TA105 NA negative TA155 IORLI negative TA155 IORLI negative TA1555 NA negative Algae at 0.0069585 Ames test non-mutagen Carcino Mouse negative Carcino Rat negative Daphnia at 2.55255 LERG inhibition ambiguous Medaka at 12.3433 Minnow at 5-4421 TA100 IORLI negative TA1555 IORLI negative	
	Quercetin, 3-o-rutinoside	Solubility 2.10e-02 mg/mt. 4.51e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -1-51 Solubility 1.43e+01 mg/mt. 3.08e-02 mol/l Class Soluble Log S (ESOL) -3-30 Solubility 3.08e-01 mg/mt. 5.05e-04 mol/l Class Soluble Log S (Ali) -4.87 Soluble Log S (Ali) -4.87 Solubility 3.10e-03 mg/mt. 1.56e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -0.29 Solubility 3.15e+02 mg/mt. 5.15e-01 mol/l Class Soluble Log S (SILICOS-IT) -0.29 Solubility 3.15e-02 mg/mt. 1.14e-04 mol/l Class Soluble Log S (SISICOS-IT) -0.20 Solubility 3.15e-02 mg/mt. 1.14e-04 mol/l Class Soluble Log S (SISICOS-IT) -0.20 mg/mt. 1.14e-04 mol/l Class	CYP2C19 inhibitor No CYP2C9 inhibitor No CYP2D6 inhibitor No CYP3A4 inhibitor No CYP3A4 inhibitor No Log Kp (skin permeation)  -8.88 cm/s  GI absorption Low BBB permeant No P-gp substrate Ves CYP1A2 inhibitor No CYP2C19 inhibitor No CYP2C9 inhibitor No CYP2C9 inhibitor No CYP2C4 inhibitor No CYP2A4 inhibitor No CYP3A4 inhibitor No CYP3A4 inhibitor No CYP3A4 inhibitor No CYP3A4 inhibitor No	Veber No; 1 violation: TPSA > 140 Egan No; 1 violation: TPSA > 131.6 Muegge No; 3 violations: TPSA > 150, H-acc > 10, H-don > 5 Bioavailability score 0.17  Lipinski No; 3 violations: MW > 500, NorO > 10, NHorOH > 5 Chose No; 4 violations: MW > 480, WLOGP < -0.4, MR > 130, #atoms > 70 Veber No; 1 violation: TPSA > 140 Egan No; 1 violation: TPSA > 131.6 Muegge No; 4 violations: MW > 600, TPSA > 131.6 Muegge No; 4 violations: MW > 600, TFSA > 131.6 Muegge No; 4 violations: MW > 600, TFSA > 131.6 Muegge	hRRG inhibition high risk Medaka at 3-7921 Minnow at 1.38214 TA100 INAL negative TA100 NA negative TA1535 I0RLI negative TA1535 I0RLI negative TA1535 NA negative TA1535 NA negative Algae at 0.0069585 Ames test non-mutagen Carcino Mouse negative Carcino Mouse negative Carcino Rat negative Daphnia at 2.5225 hERG inhibition ambiguous Medaka at 12-3433 Minnow at 5.4421 TA100 INA negative TA1535 INAL negative	
	Quercetin, 3-o-rutinoside	Solubility 2.10e-02 mg/ml. 4.51e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -1.51 Solubility 1.43e+01 mg/ml. 3.08e-02 mol/l Class Soluble Log S (ESOL) -3.30 Solubility 3.08e-01 mg/ml. 5.05e-04 mol/l Class Soluble Log S (Ali) -4.87 Solubility 8.30e-03 mg/ml. 1.36e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -0.29 Solubility 3.15e+02 mg/ml. 5.15e-01 mol/l Class Soluble Log S (SILICOS-IT) -0.29 Solubility 3.15e-02 mg/ml. 1.14e-04 mol/l Class Soluble Solubility 3.07e-0.2 mg/ml. 1.14e-04 mol/l Class	CYP2C19 inhibitor No CYP2D6 inhibitor No CYP2D6 inhibitor No CYP3A4 inhibitor No Log Kp (akin permeation)  -8.88 cm/s  GI absorption Low BBB permeant No P-gp substrate Yes CYP1A2 inhibitor No CYP2C19 inhibitor No CYP2C2 inhibitor No CYP2C3 inhibitor No CYP2C3 inhibitor No CYP2C4 inhibitor No CYP2C4 inhibitor No CYP2C5 inhibitor No CYP2C6 in	Vober No; 1 violation: TPSA>140 Egan No; 1 violation: TPSA>131.6 Mugge No; 3 violations: TPSA>150, H-acc>10, H-don>5 Bioavailability score 0.17  Lipinski No; 3 violations: MW>500, NorO>10, NHorOH>5 Ghose No; 4 violations: MW>500, NorO>10, NHorOH>5 Chose No; 4 violations: MW>480, WLOGF<0-04, MR>130, #atoms>70 Veber No; 1 violation: TPSA>140 Egan No; 1 violation: TPSA>131.6 Muggge No; 4 violations: MW>600, TPSA>150, H-acc>10, H-don>5 Bioavailability score 0.17	hRRG inhibition high risk Medaka at 3-7921 Minnow at 1.38214 TA100 10K11 negative TA100 NA negative TA155 10 RKI1 negative TA155 10 RKI1 negative TA1555 NA negative TA1555 NA negative TA1555 NA negative Carcino Mouse negative Carcino Mouse negative Daphnia at 2.55255 hERG inhibition ambiguous Medaka at 12.3433 Minnow at 5.4421 TA100 10RLI negative TA1535 NA negative TA1500 Negative	
	Quercetin, 3-o-rutinoside	Solubility 2.10e-02 mg/mt. 4.51e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -1-51 Solubility 1.43e+01 mg/mt. 3.08e-02 mol/l Class Soluble Log S (ESOL) -3-30 Solubility 3.08e-01 mg/mt. 5.05e-04 mol/l Class Soluble Log S (Ali) -4.87 Soluble Log S (Ali) -4.87 Solubility 3.10e-03 mg/mt. 1.56e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -0.29 Solubility 3.15e+02 mg/mt. 5.15e-01 mol/l Class Soluble Log S (SILICOS-IT) -0.29 Solubility 3.15e-02 mg/mt. 1.14e-04 mol/l Class Soluble Log S (SISICOS-IT) -0.20 Solubility 3.15e-02 mg/mt. 1.14e-04 mol/l Class Soluble Log S (SISICOS-IT) -0.20 mg/mt. 1.14e-04 mol/l Class	CYP2C19 inhibitor No CYP2D6 inhibitor No CYP3A4 inhibitor No CYP3A4 inhibitor No Log Kp (skin permeation)  —8.88 cm/s  GI absorption Low BBB permeant No P-89 substrate Yes CYP1A2 inhibitor No CYP2D6 inhibit	Veber No; 1 violation: TPSA > 140 Egan No; 1 violation: TPSA > 131.6 Muegge No; 3 violations: TPSA > 150, H-acc > 10, H-don > 5 Bioavailability score 0.17  Lipinski No; 3 violations: MW > 500, NorO > 10, NHorOH > 5 Chose No; 4 violations: MW > 480, WLOGP < -0.4, MR > 130, #atoms > 70 Veber No; 1 violation: TPSA > 140 Egan No; 1 violation: TPSA > 131.6 Muegge No; 4 violations: MW > 600, TPSA > 131.6 Muegge No; 4 violations: MW > 600, TFSA > 131.6 Muegge No; 4 violations: MW > 600, TFSA > 131.6 Muegge	hRRG inhibition high risk Medaka at 3-7921 Minnow at 1.38214 TA100 IORLI negative TA105 NA negative TA155 IORLI negative TA155 IORLI negative TA1555 NA negative TA1555 NA negative TA1555 NA negative Algae at 0.0069585 Ames test non-mutagen Carcino Mouse negative Carcino Rat negative Daphnia at 2.55255 hERG inhibition ambiguous Medaka at 12.3433 Minnow at 5-4421 TA100 IORLI negative TA105 IORLI negative TA105 IORLI negative TA1555 IORLI negative TA1555 IORLI negative TA1555 IORLI negative TA1568 An egative TA1575 IORLI negative	
	Quercetin, 3-o-rutinoside Synonymous Rutin	Solubility 2.10e - 22 mg/mt. 4.51e - 05 mol/l Class  Moderately soluble Log S (SILICOS-IT) -1-51 Solubility 1.43e+01 mg/mt. 3.08e-02 mol/l Class Solubile Log S (ESOL) -3-30 Solubility 3.08e-01 mg/mt. 5.08e-04 mol/l Class Solubile Log S (Ali) -4.87 Solubility 8.30e-03 mg/mt. 1.56e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -0.29 Solubility 3.15e+02 mg/mt. 1.58e-01 mol/l Class Soluble Log S (SILICOS-IT) -0.29 Solubility 5.5e-05 mol/l Class Solubile Log S (Ali) -4.59 Solubility 6.88e-03 mg/mt. 2.55e-05 mol/l Class	CYP2C19 inhibitor No CYP2D6 inhibitor No CYP2D6 inhibitor No CYP3A4 inhibitor No Log Kp (akin permeation)  -8.88 cm/s  GI absorption Low BBB permeant No P-gp substrate Ves CYP1A2 inhibitor No CYP2C19 inhibitor No CYP2C2 inhibitor No CYP2C3 inhibitor No CYP2C3 inhibitor No CYP2C4 inhibitor No CYP2C4 inhibitor No CYP2C5 inhibitor No CYP2C6 in	Veber No; 1 volation: TPSA>140 Egan No; 1 volation: TPSA>131.6 Muegge No; 3 violations: TPSA>150, H-acc>10, H-don>5 Bioavailability score 0.17  Lipinski No; 3 violations: MW>500, NorO>10, NHorOH>5 Ghose No; 4 violations: MW>480, WLOGP <-0.4, MR>130, #atoms>70 Veber No; 1 violation: TPSA>131.6 Ausgge No; 1 violation: TPSA>131.6 Sugge No; 4 violations: MW>600, TPSA>150, H-acc>10, H-don>5 Bioavailability score 0.17  Lipinski Yes; 0 violation Ghose Yes Veber Yes	hRRG inhibition high risk Medaka at 3-7821 Minnow at 1.38214 TA100 INAL negative TA105 NA negative TA155 10RLI negative TA155 10RLI negative TA1555 10RLI negative TA1535 NA negative TA1535 NA negative TA1535 NA negative Carcino Mouse negative Carcino Mouse negative Carcino Mouse negative TA150 INAL negative TA100 INA negative TA100 NA negative TA1555 INAL negative TA1555 NA pegative TA1555 NA negative	
	Quercetin, 3-o-rutinoside	Solubility 2.10e-02 mg/ml. 4.51e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -1-51 Solubility 1.43e-01 mg/ml. 3.08e-02 mol/l Class Soluble Log S (ESOL) -3.30 Solubility 3.08e-01 mg/ml. 5.05e-04 mol/l Class Soluble Log S (Ali) -4.87 Solubility 8.30e-03 mg/ml. 1.56e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -0.29 Solubility 3.15e-02 mol/l Class Soluble Log S (SILICOS-IT) -0.29 Solubility 3.15e-02 mg/ml. 1.14e-04 mol/l Class Soluble Solubility 3.94 Solubility 6.8e-02 mg/ml. 1.14e-04 mol/l Class Soluble Solubility 5.8e-03 mg/ml. 2.55e-05 mol/l Class Soluble Solubility 5.8e-03 mg/ml. 2.55e-05 mol/l Class Soluble Solubility 6.8e-03 mg/ml. 2.55e-05 mol/l Class Solubility 6.8e-03 mg/ml. 2.55e-05 mol/l Class	CYP2CI9 inhibitor No CYP2Cs inhibitor No CYP2Me inhibitor No CYP3A4 inhibitor No CYP3A4 inhibitor No Log Kp (skin permeation)  —8.88 cm/s  GI absorption Low BBB permeant No P.gp substrate Yes CYP1A2 inhibitor No CYP2CI9 inhibitor No CYP2CI9 inhibitor No CYP2CI9 inhibitor No CYP2CI9 inhibitor No CYP3A4 inhibitor No CYP3A5 inhibitor No CYP3A5 inhibitor No CYP3A6 inhibitor No	Veber No; 1 violation: TPSA > 140 Egan No; 1 violation: TPSA > 131.6 Murgge No; 3 violations: TPSA > 150, H-acc > 10, H-don > 5 Bioavailability score 0.17  Lipinski No; 3 violations: MW > 500, NorO > 10, NHorOH > 5 Ghose No; 4 violations: MW > 500, NorO > 10, NHorOH > 5 Veber No; 1 violation: TPSA > 130, #atoms > 70 Veber No; 1 violation: TPSA > 131.6 Murgge No; 1 violation: TPSA > 131.6 Murgge No; 4 violations: MW > 600, TPSA > 150, H-acc > 10, H-don > 5 Bioavailability score 0.17  Lipinski Yes; 0 violation Ghose Yes Veber Yes Egan Yes	hRRG inhibition high risk Medaka at 3-7921 Minnow at 1.8214 TA100 INAL negative TA100 NA negative TA1535 INAL negative TA1535 INAL negative TA1535 INA negative TA1535 INA negative TA1535 INA negative TA1535 INA negative Carcino Mouse negative Carcino Mouse negative Carcino Mat negative Daphnia at 2.5525 hERG inhibition ambiguous Medaka at 12.3433 Minnow at 5.4421 TA100 IORLI negative TA1535 INAL negative TA160 INA negative TA1535 INAL negative TA1535 INAL negative TA1536 INAL negative	No
	Quercetin, 3-o-rutinoside Synonymous Rutin	Solubility 2.10e-02 mg/ml. 4.51e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -1.51 Solubility 1.43e-01 mg/ml. 3.08e-02 mol/l Class Soluble Log S (ESUL) -3.30 Solubility 3.08e-01 mg/ml. 5.08e-04 mol/l Class Solubility 4.87 Solubility 8.30e-03 mg/ml. 1.56e-05 mol/l Class Moderately soluble Log S (Ali) -4.87 Solubility 8.30e-03 mg/ml. 1.56e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -0.29 Solubility 3.15e+02 mg/ml. 3.15e-01 mol/l Class Soluble Log S (SILICOS-IT) -0.29 Solubility 3.8e-03 mg/ml. 1.14e-04 mol/l Class Soluble Log S (Ali) -4.59 Solubility 6.8e-03 mg/ml. 2.55e-05 mol/l Class Soluble Log S (SILICOS-IT) -4.40	CYP2C19 inhibitor No CYP2D6 inhibitor No CYP2D6 inhibitor No CYP3D4 inhibitor No Log Kp (skin permeation)  -8.88 cm/s  GI absorption Low BBB permeant No P-89 substrate Yes CYP1A2 inhibitor No CYP2C9 inhibitor No CYP3D4 inhibitor No CYP3D4 inhibitor No CYP3D4 inhibitor No CYP3D4 inhibitor Yes CYP1A2 inhibitor Yes CYP1A2 inhibitor Yes CYP2C9 inhibitor No CYP1A2 inhibitor Yes CYP2C9 inhibitor No CYP2D5 inhibitor No	Veber No; 1 volation: TPSA>140 Egan No; 1 volation: TPSA>131.6 Muegge No; 3 violations: TPSA>150, H-acc>10, H-don>5 Bioavailability score 0.17  Lipinski No; 3 violations: MW>500, NorO>10, NHorOH>5 Ghose No; 4 violations: MW>480, WLOGP <-0.4, MR>130, #atoms>70 Veber No; 1 violation: TPSA>131.6 Ausgge No; 1 violation: TPSA>131.6 Sugge No; 4 violations: MW>600, TPSA>150, H-acc>10, H-don>5 Bioavailability score 0.17  Lipinski Yes; 0 violation Ghose Yes Veber Yes	hRRG inhibition high risk Medaka at 3-7921 Minnow at 1.8214 TA100 INAL negative TA100 NA negative TA1535 INAL negative TA1535 INAL negative TA1535 INA negative TA1535 INA negative TA1535 INA negative TA1535 INA negative Carcino Mouse negative Carcino Mouse negative Carcino Mat negative Daphnia at 2.5525 hERG inhibition ambiguous Medaka at 12.3433 Minnow at 5.4421 TA100 IORLI negative TA1535 INAL negative TA1535 INAL negative TA1535 INAL negative TA1535 INAL negative TA1536 INAL negative TA1537 INAL negative TA1537 INAL negative TA1538 INAL NEGATIVE	No
	Quercetin, 3-o-rutinoside Synonymous Rutin	Solubility 2.10e-02 mg/ml. 4.51e-05 mol/l Class  Moderately soluble Log S (SILCOS-IT) -1.51 Solubility 1.43e+01 mg/ml. 308e-02 mol/l Class Soluble Log S (ESOL) -3.30 Solubility 3.08e-01 mg/ml. 508e-04 mol/l Class Soluble Log S (Ali) -4.87 Solublity 8.30e-03 mg/ml. 1.36e-05 mol/l Class Moderately soluble Log S (SILCOS-IT) -0.29 Solubility 2.51e-02 mg/ml. 1.14e-04 mol/l Class Soluble Log S (Ali) -3.48 Solubility 3.07e-02 mg/ml. 1.14e-04 mol/l Class Soluble Log S (ESOL) -3.94 Solubility 3.07e-02 mg/ml. 1.14e-04 mol/l Class Moderately soluble Log S (SILCOS-IT) -1.51e-05 mg/ml. 2.55e-05 mol/l Class Moderately soluble Log S (SILCOS-IT) -4.40 Solubility -4.40 Solubility -4.40	CYP2CI9 inhibitor No CYP2Cs inhibitor No CYP2Me inhibitor No CYP3A4 inhibitor No CYP3A4 inhibitor No Log Kp (skin permeation)  —8.88 cm/s  GI absorption Low BBB permeant No Pegs substrate Yes CYP1A2 inhibitor No CYP2CI9 inhibitor No CYP2CI9 inhibitor No CYP2CI9 inhibitor No CYP2Me inhibitor No CYP3A5 inhibitor No CYP3A6 inhibitor No CYP3A6 inhibitor No CYP3A6 inhibitor No CYP3A6 inhibitor Yes CYP4CI9 inhibitor No CYP1A7 inhibitor Yes CYP2CI9 inhibitor No CYP2CI9 inhibitor Yes	Veber No; 1 volation: TPSA>140 Egan No; 1 volation: TPSA>131.6 Muegge No; 3 violations: TPSA>150, H-acc>10, H-don>5 Bioavailability score 0.17  Lipinski No; 3 violations: MW>500, NorO>10, NHorOH>5 Ghose No; 4 violations: MW>480, WLOGP<0.4, MR>130, #atoms>70 Veber No; 1 violation: TPSA>131.6 Muegge No; 1 violation: TPSA>131.6 Muegge No; 4 violations: MW>600, TPSA>150, H-acc>10, H-don>5 Bioavailability score 0.17  Lipinski Yes; 0 violation Ghose Yes Veber Yes Fgan Yes Muegge Yes	hRRG inhibition high risk Medaka at 3-79-21 Minnow at 1.38214 TA100 IoRL negative TA100 NA negative TA155 IORLI negative TA155 IORLI negative TA1555 NA negative TA1555 NA negative TA1555 NA negative Algae at 0.0669585 Ames test non-mutagen Carcino Mouse negative Carcino Rat negative Daphnia at 2.55255 hRG inhibition ambiguous Medaka at 12-3433 Minnow at 5.44210 TA100 IORLI negative TA100 NA negative TA1555 IORLI negative	No
	Quercetin, 3-o-rutinoside Synonymous Rutin	Solubility 2.10e-02 mg/mt. 4.51e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -1-51 Solubility 1.43e+01 mg/mt, 3.08e-02 mol/l Class Soluble Log S (ESOL) -3-30 Solubility 3.08e-01 mg/mt, 3.08e-04 mol/l Class Soluble Log S (Ail) -4-87 Solubility 3.08e-03 mg/mt, 1.36e-05 mol/l Class Soluble Log S (SILICOS-IT) -0.29 Solubility 3.15e-02 mg/mt, 1.36e-05 mol/l Class Soluble Log S (SILICOS-IT) -0.29 Solubility 3.15e-02 mg/mt, 3.15e-01 mol/l Class Soluble Log S (SILICOS-IT) -0.29 Solubility 3.15e-03 mg/mt, 1.4e-04 mol/l Class Soluble Log S (SILICOS-IT) -0.28 mg/mt, 2.55e-05 mol/l Class Soluble Log S (SILICOS-IT) -0.40 Solubility 6.88e-03 mg/mt, 1.4e-04 mol/l Class Soluble Log S (SILICOS-IT) -4.40 Solubility Log S (SILICOS-IT) -4.40 Solubility L07e-02 mg/mt, 3.49e-05 mol/l Log S (SILICOS-IT)	CYP2C19 inhibitor No CYP2D6 inhibitor No CYP2D6 inhibitor No CYP3D4 inhibitor No Log Kp (skin permeation)  -8.88 cm/s  GI absorption Low BBB permeant No P-89 substrate Yes CYP1A2 inhibitor No CYP2C9 inhibitor No CYP3D4 inhibitor No CYP3D4 inhibitor No CYP3D4 inhibitor No CYP3D4 inhibitor Yes CYP1A2 inhibitor Yes CYP1A2 inhibitor Yes CYP2C9 inhibitor No CYP1A2 inhibitor Yes CYP2C9 inhibitor No CYP2D5 inhibitor No	Veber No; 1 volation: TPSA>140 Egan No; 1 volation: TPSA>131.6 Muegge No; 3 violations: TPSA>150, H-acc>10, H-don>5 Bioavailability score 0.17  Lipinski No; 3 violations: MW>500, NorO>10, NHorOH>5 Ghose No; 4 violations: MW>480, WLOGP<0.4, MR>130, #atoms>70 Veber No; 1 violation: TPSA>131.6 Muegge No; 1 violation: TPSA>131.6 Muegge No; 4 violations: MW>600, TPSA>150, H-acc>10, H-don>5 Bioavailability score 0.17  Lipinski Yes; 0 violation Ghose Yes Veber Yes Fgan Yes Muegge Yes	hRRG inhibition high risk Medaka at 3-7921 Minnow at 1.8214 TA100 IORLI negative TA100 NA negative TA1535 IORLI negative Carcino Mouse negative TA1505 IORLI negative TA100 IORLI negative TA100 IORLI negative TA1535 IORLI negative TA1535 IORLI negative TA1535 IORLI negative TA1536 IORLI negative TA1536 IORLI negative TA1537 IORLI Negative TA1538 IORLI Negative	No
	Quercetin, 3-o-rutinoside Synonymous Rutin	Solubility 2.10e-02 mg/ml. 4.51e-05 mol/l Class  Moderately soluble Log S (SILCOS-IT) -1.51 Solubility 1.43e+01 mg/ml. 308e-02 mol/l Class Soluble Log S (ESOL) -3.30 Solubility 3.08e-01 mg/ml. 508e-04 mol/l Class Soluble Log S (Ali) -4.87 Solublity 8.30e-03 mg/ml. 1.36e-05 mol/l Class Moderately soluble Log S (SILCOS-IT) -0.29 Solubility 2.51e-02 mg/ml. 1.14e-04 mol/l Class Soluble Log S (Ali) -3.48 Solubility 3.07e-02 mg/ml. 1.14e-04 mol/l Class Soluble Log S (ESOL) -3.94 Solubility 3.07e-02 mg/ml. 1.14e-04 mol/l Class Moderately soluble Log S (SILCOS-IT) -1.51e-05 mg/ml. 2.55e-05 mol/l Class Moderately soluble Log S (SILCOS-IT) -4.40 Solubility -4.40 Solubility -4.40	CYP2CI9 inhibitor No CYP2Cs inhibitor No CYP2Me inhibitor No CYP3A4 inhibitor No CYP3A4 inhibitor No Log Kp (skin permeation)  —8.88 cm/s  GI absorption Low BBB permeant No Pegs substrate Yes CYP1A2 inhibitor No CYP2CI9 inhibitor No CYP2CI9 inhibitor No CYP2CI9 inhibitor No CYP2Me inhibitor No CYP3A5 inhibitor No CYP3A6 inhibitor No CYP3A6 inhibitor No CYP3A6 inhibitor No CYP3A6 inhibitor Yes CYP4CI9 inhibitor No CYP1A7 inhibitor Yes CYP2CI9 inhibitor No CYP2CI9 inhibitor Yes	Veber No; 1 volation: TPSA>140 Egan No; 1 volation: TPSA>131.6 Muegge No; 3 violations: TPSA>150, H-acc>10, H-don>5 Bioavailability score 0.17  Lipinski No; 3 violations: MW>500, NorO>10, NHorOH>5 Ghose No; 4 violations: MW>480, WLOGP<0.4, MR>130, #atoms>70 Veber No; 1 violation: TPSA>131.6 Muegge No; 1 violation: TPSA>131.6 Muegge No; 4 violations: MW>600, TPSA>150, H-acc>10, H-don>5 Bioavailability score 0.17  Lipinski Yes; 0 violation Ghose Yes Veber Yes Fgan Yes Muegge Yes	hRRG inhibition high risk Medaka at 3-79-21 Minnow at 1.38214 TA100 IoRL negative TA100 NA negative TA155 IORLI negative TA155 IORLI negative TA1555 NA negative TA1555 NA negative TA1555 NA negative Algae at 0.0669585 Ames test non-mutagen Carcino Mouse negative Carcino Rat negative Daphnia at 2.55255 hRG inhibition ambiguous Medaka at 12-3433 Minnow at 5.44210 TA100 IORLI negative TA100 NA negative TA1555 IORLI negative	No
	Quercetin, 3-o-rutinoside Synonymous Rutin	Solubility 2.10e-02 mg/ml, 4.51e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -1.51 Solubility 1.43e+01 mg/ml, 3.08e-02 mol/l Class Soluble Log S (ESOL) -3.30 Solubility 3.08e-01 mg/ml, 3.08e-04 mol/l Class Solubile Log S (Ali) -4.87 Solubility 8.30e-03 mg/ml, 1.36e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -0.29 Solubility 3.15e+02 mg/ml, 3.15e-01 mol/l Class Soluble Log S (SISOL) -3.94 Solubility 3.07e-02 mg/ml, 1.14e-04 mol/l Class Moderately soluble Log S (SISOL) Solubility Solubility 3.07e-02 mg/ml, 1.14e-04 mol/l Class Moderately soluble Log S (SISOL) Solubility 3.07e-02 mg/ml, 3.15e-01 mol/l Class Solubility 3.07e-02 mg/ml, 3.14e-04 mol/l Class Solubility 3.07e-02 mg/ml, 3.14e-05 mol/l Class Moderately soluble Log S (SICICOS-IT) -4.40 Solubility 3.07e-05 mol/l Class Moderately soluble Log S (SICICOS-IT) -4.40 Solubility 6.5 (ESOL)	CYP2CI9 inhibitor No CYP2Cs inhibitor No CYP2Me inhibitor No CYP3A4 inhibitor No CYP3A4 inhibitor No Log Kp (skin permeation)  —8.88 cm/s  GI absorption Low BBB permeant No Pegs substrate Yes CYP1A2 inhibitor No CYP2CI9 inhibitor No CYP2CI9 inhibitor No CYP2CI9 inhibitor No CYP2Me inhibitor No CYP3A5 inhibitor No CYP3A6 inhibitor No CYP3A6 inhibitor No CYP3A6 inhibitor No CYP3A6 inhibitor Yes CYP4CI9 inhibitor No CYP1A7 inhibitor Yes CYP2CI9 inhibitor No CYP2CI9 inhibitor Yes	Veber No; 1 volation: TPSA>140 Egan No; 1 volation: TPSA>131.6 Muegge No; 3 violations: TPSA>150, H-acc>10, H-don>5 Bioavailability score 0.17  Lipinski No; 3 violations: MW>500, NorO>10, NHorOH>5 Ghose No; 4 violations: MW>480, WLOGP<0.4, MR>130, #atoms>70 Veber No; 1 violation: TPSA>131.6 Muegge No; 1 violation: TPSA>131.6 Muegge No; 4 violations: MW>600, TPSA>150, H-acc>10, H-don>5 Bioavailability score 0.17  Lipinski Yes; 0 violation Ghose Yes Veber Yes Fgan Yes Muegge Yes	hRRG inhibition high risk Medaka at 3-7921 Minnow at 1.8214 TA100 IORLI negative TA100 NA negative TA1535 IORLI negative Carcino Mouse negative TA1505 IORLI negative TA100 IORLI negative TA100 IORLI negative TA1535 IORLI negative TA1535 IORLI negative TA1535 IORLI negative TA1536 IORLI negative TA1536 IORLI negative TA1537 IORLI Negative TA1538 IORLI Negative	No
Citrus reticulata Blanco	Quercetin, 3-o-rutinoside Synonymous Rutin	Solubility 2.10e-02 mg/ml. 4.51e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -1-51 Solubility 1.43e+01 mg/ml. 3.08e-02 mol/l Class Solubile Log S (ESOL) -3-30 Solubility 3.08e-01 mg/ml. 5.05e-04 mol/l Class Solubile Log S (Ali) -4-487 Solubility 3.09e-03 mg/ml. 1.56e-05 mol/l Class Solubile Log S (SILICOS-IT) -0.29 Solubility 3.15e+02 mg/ml. 1.14e-04 mol/l Class Solubility 3.15e-02 mg/ml. 1.14e-04 mol/l Class Solubility Solubility 3.15e-05 mol/l Class Solubility 3.15e-05 mol/l Class Solubility 3.15e-05 mol/l Class Solubility 1.07e-02 mg/ml. 1.15e-05 mol/l Class Solubility Log S (SILICOS-IT) -4.40 Log S (SILICOS-IT) -4.40 Log S (SILICOS-IT) -4.40 Log S (SILICOS-IT) -4.40 Log S (SILICOS-IT) -3-40 Log S (SILICOS-IT) -3-28	CYP2CI9 inhibitor No CYP2Cs inhibitor No CYP2Me inhibitor No CYP3A4 inhibitor No CYP3A4 inhibitor No Log Kp (skin permeation)  —8.88 cm/s  GI absorption Low BBB permeant No Pegs substrate Yes CYP1A2 inhibitor No CYP2CI9 inhibitor No CYP2CI9 inhibitor No CYP2CI9 inhibitor No CYP2CI9 inhibitor No CYP3A5 inhibitor No CYP3A6 inhibitor No CYP3A6 inhibitor No CYP3A6 inhibitor No CYP3A6 inhibitor Yes CYP3CI9 inhibitor No CYP3CI9 inhibitor Yes CYP3CI9 inhibitor Yes	Veber No; 1 volation: TPSA>140 Egan No; 1 volation: TPSA>131.6 Muegge No; 3 violations: TPSA>150, H-acc>10, H-don>5 Bioavailability score 0.17  Lipinski No; 3 violations: MW>500, NorO>10, NHorOH>5 Ghose No; 4 violations: MW>480, WLOGP<0.4, MR>130, #atoms>70 Veber No; 1 violation: TPSA>131.6 Muegge No; 1 violation: TPSA>131.6 Muegge No; 4 violations: MW>600, TPSA>150, H-acc>10, H-don>5 Bioavailability score 0.17  Lipinski Yes; 0 violation Ghose Yes Veber Yes Fgan Yes Muegge Yes	hRRG inhibition high risk Medaka at 3-7921 Minnow at 1.8214 TA100 IORLI negative TA100 NA negative TA1535 IORLI negative Carcino Mouse negative TA1505 IORLI negative TA100 IORLI negative TA100 IORLI negative TA1535 IORLI negative TA1535 IORLI negative TA1535 IORLI negative TA1536 IORLI negative TA1536 IORLI negative TA1537 IORLI Negative TA1538 IORLI Negative	No
Citrus reticulata Blanco	Quercetin, 3-o-rutinoside Synonymous Rutin	Solubility 2.10e-02 mg/ml, 4.51e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -1.51 Solubility 1.43e+01 mg/ml, 3.08e-02 mol/l Class Soluble Log S (ESOL) -3.30 Solubility 3.08e-01 mg/ml, 3.08e-04 mol/l Class Solubile Log S (Ali) -4.87 Solubility 8.30e-03 mg/ml, 1.36e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -0.29 Solubility 3.15e+02 mg/ml, 3.15e-01 mol/l Class Solubility Solubility Solubility 1.07e-02 mg/ml, 1.14e-04 mol/l Class Moderately soluble Log S (SICOS-IT) -0.29 Solubility 3.07e-02 mg/ml, 1.14e-04 mol/l Class Solubility Solubility 3.07e-02 mg/ml, 3.15e-01 mol/l Class Solubility 3.07e-02 mg/ml, 3.14e-05 mol/l Class Solubility 3.07e-02 mg/ml, 3.07e-05 mol/l Class Moderately soluble Log S (SICICOS-IT) -4.40 Moderately soluble Log S (ESOL) -3.28 Solubility	CYP2CI9 inhibitor No CYP2Cs inhibitor No CYP2Me inhibitor No CYP3A4 inhibitor No CYP3A4 inhibitor No Log Kp (skin permeation)  —8.88 cm/s  GI absorption Low BBB permeant No Pegs substrate Yes CYP1A2 inhibitor No CYP2CI9 inhibitor No CYP2CI9 inhibitor No CYP2CI9 inhibitor No CYP2CI9 inhibitor No CYP3A5 inhibitor No CYP3A6 inhibitor No CYP3A6 inhibitor No CYP3A6 inhibitor No CYP3A6 inhibitor Yes CYP3CI9 inhibitor No CYP3CI9 inhibitor Yes CYP3CI9 inhibitor Yes	Veber No; 1 violation: TPSA > 140 Egan No; 1 violation: TPSA > 131.6 Murgge No; 3 violations: TPSA > 150, H-acc > 10, H-don > 5 Bioavailability score 0.17  Lipinski No; 3 violations: MW > 500, NorO > 10, NHorOH > 5 Chose No; 4 violations: MW > 480, WLOGP < −0.4, MR > 130, #atoms > 70 Veber No; 1 violation: TPSA > 131.6 Murgge No; 1 violation: TPSA > 131.6 Murgge No; 4 violations: MW > 600, TPSA > 131.6 Murgge No; 4 violations: MW > 600, TPSA > 150, H-acc > 10, H-don > 5 Bioavailability score 0.17  Lipinski Ye; 0 violation Ghose Yes Veber Yes Egan Yes Murgge Yes Bioavailability Score 0.55	hRRG inhibition high risk Medala at 3.7921 Minnow at 1.38214 TA100 IORLI negative TA105 NA negative TA155 IORLI negative TA155 TORLI negative TA1555 NA negative TA1555 NA negative TA1555 NA negative Algae at 0.0069585 Ames test non-mutagen Carcino Mouse negative Carcino Rat negative Daphnia at 2.55255 hERG inhibition ambiguous Minnow at 5.4421 TA100 IORLI negative TA105 NA negative TA105 NA negative TA1555 NA negative TA1555 IORLI positive TA1555 IORLI positive TA1555 IORLI positive TA1555 IORLI negative	No
Citrus reticulata Blanco	Quercetin, 3-o-rutinoside Synonymous Rutin	Solubility 2.10e-02 mg/ml. 4.51e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -1-51 Solubility 1.43e+01 mg/ml. 3.08e-02 mol/l Class Solubile Log S (ESOL) -3-30 Solubility 3.08e-01 mg/ml. 5.05e-04 mol/l Class Solubile Log S (Ali) -4-487 Solubility 3.09e-03 mg/ml. 1.56e-05 mol/l Class Solubile Log S (SILICOS-IT) -0.29 Solubility 3.15e+02 mg/ml. 1.14e-04 mol/l Class Solubility 3.15e-02 mg/ml. 1.14e-04 mol/l Class Solubility Solubility 3.15e-05 mol/l Class Solubility 3.15e-05 mol/l Class Solubility 3.15e-05 mol/l Class Solubility 1.07e-02 mg/ml. 1.15e-05 mol/l Class Solubility Log S (SILICOS-IT) -4.40 Log S (SILICOS-IT) -4.40 Log S (SILICOS-IT) -4.40 Log S (SILICOS-IT) -4.40 Log S (SILICOS-IT) -3-40 Log S (SILICOS-IT) -3-28	CYP2C19 inhibitor No CYP2D6 inhibitor No CYP2D6 inhibitor No CYP3A4 inhibitor No CYP3A4 inhibitor No Log Kp (skin permeation)  —8.88 cm/s  GI absorption Low BBB permeant No Pgg substrate Yes CYP1A2 inhibitor No CYP2D6 inhibitor No CYP2D6 inhibitor No CYP2D6 inhibitor No CYP2D6 inhibitor No CYP3A6 inhibitor No CYP1A7 inhibitor Yes CYP2D9 inhibitor No CYP2D6 inhibitor Yes CYP2D6 inhibitor Yes CYP2D6 inhibitor Yes CYP3A6 inhibitor Yes C	Veber No; 1 volation: TFSA > 140 Egan No; 1 volation: TFSA > 131.6 Musegge No; 3 violations: TFSA > 150, H-acc > 10, H-don > 5 Bioavailability score 0.17  Lipinski No; 3 violations: MW > 500, NorO > 10, NHorOH > 5 Ghose No; 4 violations: MW > 80, WLOGF > -0.4, MR > 130, #atoms > 70 Veber No; 1 violation: TFSA > 140 Egan No; 1 violation: TFSA > 13.6 Musegge No; 4 violations: MW > 600, TFSA > 150, H-acc > 10, H-don > 5 Bioavailability score 0.17  Lipinski Yes; 0 violation Ghose Yes Veber Yes Egan Yes Musegge Yes Bioavailability Score 0.55	hRRG inhibition high risk Medaka at 3-7921 Minnow at 1.8214 TA100 IORLI negative TA100 NA negative TA1535 IORLI negative Carcino Mouse negative TA1505 IORLI negative TA100 IORLI negative TA100 IORLI negative TA1535 IORLI negative TA1535 IORLI negative TA1535 IORLI negative TA1536 IORLI negative TA1536 IORLI negative TA1537 IORLI Negative TA1538 IORLI Negative	No
Citrus reticulata Blanco	Quercetin, 3-o-rutinoside Synonymous Rutin	Solubility 2.10e - 22 mg/ml. 4.51e - 05 mol/l Class Moderately soluble Log S (SILICOS-IT) -1.51 Solubility 1.43e + 01 mg/ml. 3.08e - 02 mol/l Class Solubile Log S (ESOL) -3.30 Solubility 3.08e - 01 mg/ml. 5.05e - 04 mol/l Class Solubile Log S (Ali) -4.87 Solubility 3.09e - 03 mg/ml. 1.56e - 05 mol/l Class Solubile Log S (Ali) -4.87 Solubility 3.15e - 03 mg/ml. 1.56e - 05 mol/l Class Solubile Log S (SILICOS-IT) -0.29 Solubility 3.15e - 02 mg/ml. 1.14e - 04 mol/l Class Solubile Log S (SISICOS-IT) -0.29 Solubility 3.15e - 05 mg/ml. 1.14e - 04 mol/l Class Solubile Log S (SISICOS-IT) -4.40 Solubility 3.07e - 0.5 mg/ml. 2.55e - 05 mol/l Class Solubile Log S (SILICOS-IT) -4.40 Solubility 3.98e - 05 mg/ml. 2.55e - 05 mol/l Class Moderately soluble Log S (SILICOS-IT) -4.40 Solubility 1.07e - 0.2 mg/ml. 3.94e - 0.5 mol/l Class Moderately soluble Log S (ESOL) -3.28 Solubility 3.19e - 01 mg/ml. 3.94e - 05 mol/l Class Solubility 3.19e - 01 mg/ml. 3.94e - 05 mol/l Class Solubility 3.19e - 01 mg/ml. 5.25e - 04 mol/l Class	CYPZC19 inhibitor No CYPZC3 inhibitor No CYP2A6 inhibitor No CYP3A4 inhibitor No CYP3A4 inhibitor No Log Kp (skin permeation)  —8.88 cm/s  GI absorption Low BBB permeant No P-gn substrate Yes CYP1A2 inhibitor No CYPZC19 inhibitor No CYPZC19 inhibitor No CYPZC30 inhibitor No CYPZC30 inhibitor No CYPZC30 inhibitor No CYPZA6 inhibitor No CYPZA6 inhibitor No CYPZA6 inhibitor No CYPZC19 inhibitor No CYPZC3 inhibitor No CYPZC3 inhibitor No CYPZC3 inhibitor No CYPZC3 inhibitor No CYPZC6 inhibitor No CYPZC6 inhibitor No CYPZC6 inhibitor No CYPZC7 inhibitor No CYPZC7 inhibitor No CYPZC8 inhibitor Yes CYPZA6 inhibitor Yes CYPZA6 inhibitor Yes CYPZA6 inhibitor Yes CYPZC9 inhibitor No CYPZC9 inhibitor	Veber No; 1 violation: TPSA > 140 Egan No; 1 violation: TPSA > 131.6 Murgge No; 3 violations: TPSA > 150, H-acc > 10, H-don > 5 Bioavailability score 0.17  Lipinski No; 3 violations: MW > 500, NorO > 10, NHorOH > 5 Ghose No; 4 violations: MW > 480, WLOGP < −0.4, MR > 130, #atoms > 70 Veber No; 1 violation: TPSA > 131.6 Murgge No; 1 violation: TPSA > 131.6 Murgge No; 4 violations: MW > 600, TPSA > 131.6 Murgge No; 4 violations: MW > 600, TPSA > 150, H-acc > 10, H-don > 5 Bioavailability score 0.17  Lipinski Yes; 0 violation Ghose Yes Veber Yes Egan Yes Murgge Yes Bioavailability Score 0.55	hRRG inhibition high risk Medaka at 3.73921 Minnow at 1.38214 TA100 10RLI negative TA109 NA negative TA1551 10RLI negative TA1555 10RLI negative TA1555 10RLI negative TA1555 10RLI negative TA1555 NA negative TA1555 NA negative Carcino Mouse negative Carcino Mouse negative Carcino Mouse negative Carcino Att negative Daphnia at 2.54255 hERG inhibition ambiguous Medaka at 12.3433 Minnow at 5.4421 TA100 10RLI negative TA100 NA negative TA1555 10RLI negative TA1555 NA negative	No
Citrus reticulata Blanco	Quercetin, 3-o-rutinoside Synonymous Rutin	Solubility 2.10e-02 mg/ml. 4.51e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -1.51 Solubility 1.43e+01 mg/ml. 3.08e-02 mol/l Class Soluble Log S (ESDL) -3.30 Solubility 3.08e-01 mg/ml. 5.05e-04 mol/l Class Soluble Log S (Ali) -4.87 Solubility 8.30e-03 mg/ml. 1.36e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -0.29 Solubility 3.15e+02 mg/ml. 5.15e-01 mol/l Class Soluble Log S (ESDL) -3.94 Solubility 3.07e-02 mg/ml. 1.14e-04 mol/l Class Soluble Log S (SILICOS-IT) -4.60 Solubility 3.07e-02 mg/ml. 1.14e-04 mol/l Class Moderately soluble Log S (SILICOS-IT) -4.40 Solubility 3.07e-02 mg/ml. 3.15e-01 mol/l Class Moderately soluble Log S (SILICOS-IT) -4.40 Solubility 3.4e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -4.25 Solubility 1.07e-02 mg/ml ; 3.3e-05 mol/l Class Soluble Log S (ESDL) -3.28 Soluble Log S (Ali)	CYP2CI9 inhibitor No CYP2De inhibitor No CYP2De inhibitor No CYP3De inhibitor No CYP3De inhibitor No Log Kp (skin permeation)  -8.88 cm/s  GI absorption Low BBB permeant No P-89 substrate Yes CYP1A2 inhibitor No CYP2CI9 inhibitor No CYP3De in	Veber No; 1 volation: TFSA > 140 Egan No; 1 volation: TFSA > 131.6 Musegge No; 3 violations: TFSA > 150, H-acc > 10, H-don > 5 Bioavailability score 0.17  Lipinski No; 3 violations: MW > 500, NorO > 10, NHorOH > 5 Ghose No; 4 violations: MW > 80, WLOGF < 0.4, MR > 130, #atoms > 70 Veber No; 1 violation: TFSA > 140 Egan No; 1 violation: TFSA > 13.6 Musegge No; 4 violations: MW > 600, TFSA > 13.6 Musegge No; 4 violations: MW > 600, TFSA > 100, H-acc > 10, H-don > 5 Bioavailability score 0.17  Lipinski Yes; 0 violation Ghose Yes Veber Yes Egan Yes Musegge Yes Bioavailability Score 0.55  Lipinski No; 3 violations: MW > 500, NorO > 10, NHorOH > 5 Ghose Chose	hRRG inhibition high risk Medaka at 3-7921 Minnow at 1.38214 TA100 IORLI negative TA105 NA negative TA105 NA negative TA105 NA negative TA155 IORLI negative TA155 IORLI negative TA155 NA negative TA155 NA negative TA155 NA negative Daphnia at 2.5525 ERG inhibition ambiguous Medaka at 12.3433 Minnow at 5-4421 TA100 IORLI negative TA155 IORLI negative TA105 NA negative TA105 NA negative TA106 IORLI negative TA107 Na negative TA108 Na negative TA108 Na negative TA155 IORLI negative TA155 IORLI negative TA155 NA negative TA155 IORLI negative	No
Citrus reticulata Blanco	Quercetin, 3-o-rutinoside Synonymous Rutin Apigenin	Solubility 2.10e-22 mg/mt. 4.51e-05 mol/l Class  Moderately soluble Log S (SILICOS-IT) -1-51 Solubility 1.43e+01 mg/mt. 3.08e-02 mol/l Class Soluble Log S (ESOL) -3.30 Solubility 3.08e-01 mg/mt. 3.08e-04 mol/l Class Solubile Log S (Ali) -4.87 Solubility 8.30e-03 mg/mt. 1.36e-05 mol/l Class Solubility 8.30e-03 mg/mt. 1.36e-05 mol/l Class Solubility 8.30e-03 mg/mt. 1.36e-01 mol/l Class Solubility Solubility 8.30e-03 mg/mt. 1.36e-05 mol/l Class Solubility Log S (SILICOS-IT) -0.29 Solubility 3.15e-02 mg/mt. 3.15e-01 mol/l Class Solubile Log S (Ali) -4.59 Solubility 8.88e-03 mg/mt. 2.55e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -4.40 Solubility 1.07e-02 mg/mt. 3.94e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -4.40 Solubility 1.07e-02 mg/mt. 3.94e-05 mol/l Class Moderately soluble Log S (ESOL) -3.28 Solubility 1.07e-02 mg/mt. 3.94e-05 mol/l Class Moderately soluble Log S (ESOL) -3.28 Solubility 1.07e-02 mg/mt. 3.94e-05 mol/l Class Moderately soluble Log S (ESOL) -3.28 Solubility 1.07e-04 mg/mt. 3.24e-04 mol/l Class	CYPZC19 inhibitor No CYPZOS inhibitor No CYP2A6 inhibitor No CYP3A4 inhibitor No CYP3A4 inhibitor No Log Kp (skin permeation)  —8.88 cm/s  GI absorption Low BBB permeant No P-gs substrate Ye CYP4A2 inhibitor No CYP2C19 inhibitor No CYP2C19 inhibitor No CYP2A3 inhibitor No CYP2A3 inhibitor No CYP2A5 inhibitor No CYP3A4 inhibitor No CYP3A5 inhibitor No CYP3A5 inhibitor No CYP3A6 inhibitor Yo CYP3A6 inhibitor Ye CYP3A6 inhibitor No BBB permeant No P-gs substrate Ye CYP4A6 inhibitor No	Veber No; 1 volation: TFSA > 140 Egan No; 1 volation: TFSA > 131.6 Musegge No; 3 violations: TFSA > 150, H-acc > 10, H-don > 5 Bioavailability score 0.17  Lipinski No; 3 violations: MW > 500, NorO > 10, NHorOH > 5 Ghose No; 4 violations: MW > 500, NorO > 10, NHorOH > 5 Veber No; 1 violation: TFSA > 140 Egan No; 1 violation: TFSA > 13.6 Musegge No; 4 violations: MW > 600, TFSA > 13.6 Musegge No; 4 violations: MW > 600, TFSA > 150, H-acc > 10, H-don > 5 Bioavailability score 0.17  Lipinski Yes; 0 violation Ghose Yes Veber Yes Egan Yes Musege Yes Bioavailability Score 0.55  Lipinski No; 3 violations: MW > 500, NorO > 10, NHorOH > 5 Ghose Musege Yes Bioavailability Score 0.55  No; 3 violations: MW > 500, NorO > 10, NHorOH > 5 Ghose No; 4 violations: MW > 580, WLOGF < 0.4, MR > 130, #atoms > 70 Veber	hRRG inhibition high risk Medaka at 3.73921 Minnow at 1.38214 TA100 10RL negative TA109 NA negative TA155 10RLI negative Daphnia at 2.5825 hRRG inhibition ambiguous Medaka at 12.3433 Minnow at 5.4421 TA100 10RLI negative TA100 NA negative TA155 10RLI negative TA155 10RLI negative TA155 NA negative TA155 10RLI negative TA156 10RLI negative TA157 10RLI negative Carcino Rat 10961213	No
Zitrus reticulata Blanco	Quercetin, 3-o-rutinoside Synonymous Rutin	Solubility 2.10e-02 mg/ml. 4.51e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -1.51 Solubility 1.43e+01 mg/ml. 308e-02 mol/l Class Soluble Log S (ESDL) -3.30 Solubility 3.08e-01 mg/ml. 5.05e-04 mol/l Class Soluble Log S (Ali) -4.87 Solubility 8.30e-03 mg/ml. 1.3ee-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -0.29 Solubility 3.15e+02 mg/ml. 5.15e-01 mol/l Class Soluble Log S (SILICOS-IT) -1.20 mg/ml. 1.14e-04 mol/l Class Solubility 3.15e+02 mg/ml. 1.14e-05 mol/l Class Solubility 3.15e-02 mg/ml. 1.14e-04 mol/l Class Solubility 1.07e-02 mg/ml. 1.14e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -4.40 Solubility 1.07e-02 mg/ml. 3.34e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -4.40 Solubility 1.07e-02 mg/ml. 3.32e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -4.40 Solubility 1.07e-02 mg/ml. 3.32e-05 mol/l Class Soluble Log S (LSICOS-IT) -3.28 Soluble Log S (Ali) -4.33 Solublity	CYP2CI9 inhibitor No CYP2De inhibitor No CYP2De inhibitor No CYP3De inhibitor No CYP3De inhibitor No Log Kp (skin permeation)  -8.88 cm/s  GI absorption Low BBB permeant No P-89 substrate Yes CYP1A2 inhibitor No CYP2CI9 inhibitor No CYP3De in	Veber No; 1 violation: TPSA > 140 Egan No; 1 violation: TPSA > 131.6 Murgge No; 3 violations: TPSA > 150, H-acc > 10, H-don > 5 Bioavailability score 0.17  Lipinski No; 3 violations: MW > 500, NorO > 10, NHorOH > 5 Ghose No; 4 violations: MW > 480, WLOGP < −0.4, MR > 130, #atoms > 70 Veber No; 1 violation: TPSA > 131.6 Murgge No; 1 violation: TPSA > 131.6 Murgge No; 4 violations: MW > 600, TPSA > 130, H-acc > 10, H-don > 5 Bioavailability score 0.17  Lipinski Yes; 0 violation Ghose Yes Veber Yes Egan Yes Murgge Yes Bioavailability Score 0.55  No; 4 violations: MW > 500, NorO > 10, NHorOH > 5 Ghose No; 4 violations: MW > 500, NorO > 10, NHorOH > 5 No; 4 violations: MW > 500, NorO > 10, NHorOH > 5 No; 4 violations: MW > 500, NorO > 10, NHorOH > 5 No; 4 violations: MW > 480, WLOGP < −0.4, MR > 130, #atoms > 70 Veber No; 4 violation: MW > 480, WLOGP < −0.4, MR > 130, #atoms > 70 Veber No; 4 violation: TPSA > 140	hRRG inhibition high risk Medaka at 3-7921 Minnow at 1.38214 TA100 IORLI negative TA105 NA negative TA105 NA negative TA105 NA negative TA155 IORLI negative TA155 IORLI negative TA155 NA negative TA155 NA negative TA155 NA negative Daphnia at 2.5525 ERG inhibition ambiguous Medaka at 12.3433 Minnow at 5-4421 TA100 IORLI negative TA155 IORLI negative TA105 NA negative TA105 NA negative TA106 IORLI negative TA107 Na negative TA108 Na negative TA108 Na negative TA155 IORLI negative TA155 IORLI negative TA155 NA negative TA155 IORLI negative	No
Zitrus reticulata Blanco	Quercetin, 3-o-rutinoside Synonymous Rutin Apigenin	Solubility 2.10e-02 mg/ml. 4.51e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -1-51 Solubility 1.43e+01 mg/ml. 3.08e-02 mol/l Class Soluble Log S (ESOL) -3.00 Solubility 3.08e-01 mg/ml. 5.05e-04 mol/l Class Soluble Log S (Ali) -4.87 Solubility 8.30e-03 mg/ml. 1.36e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -0.29 Solubility 3.15e+02 mg/ml. 3.15e-01 mol/l Class Soluble Log S (SILICOS-IT) -0.20 mg/ml. 1.14e-04 mol/l Class Soluble Log S (SICOS-IT) -0.20 mg/ml. 1.14e-04 mol/l Class Soluble Log S (SICOS-IT) -4.80 Solubility 3.07e-02 mg/ml. 1.14e-04 mol/l Class Soluble Log S (SILICOS-IT) -4.40 Solubility 1.07e-02 mg/ml. 1.14e-04 mol/l Class Moderately soluble Log S (SILICOS-IT) -4.40 Solubility 1.07e-02 mg/ml. 3.94e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -4.40 Solubility 1.07e-01 mg/ml. 3.24e-05 mol/l Class Soluble Log S (Ali) -3.28e-02 mg/ml. 4.72e-05 mol/l Class Soluble Log S (Ali) -4.31 Solublity 2.88e-02 mg/ml. 4.72e-05 mol/l Class	CYP2C19 inhibitor No CYP2A5 inhibitor No CYP2A6 inhibitor No CYP2A6 inhibitor No CYP3A6 inhibitor No Log Kp (skin permeation)  —8.88 cm/s  GI absorption Low BBB permeant No P-gs substrate Yes CYP1A2 inhibitor No CYP2C19 inhibitor No CYP2C3 inhibitor No CYP2A5 inhibitor No CYP2A6 inhibitor No CYP3A6 inhibitor No CYP3A6 inhibitor No CYP3A6 inhibitor No CYP3A6 inhibitor Yes CYP3A7 inhibitor Yes CYP3A7 inhibitor Yes CYP3A8 inhibitor No CYP3A8 inhibitor Yes CYP3A8 inhibitor No CYP3A9 inhibitor No	Veber No; 1 volation: TFSA > 140 Egan No; 1 volation: TFSA > 131.6 Musegge No; 3 violations: TFSA > 150, H-acc > 10, H-don > 5 Bioavailability score 0.17  Lipinski No; 3 violations: MW > 500, NorO > 10, NHorOH > 5 Ghose No; 4 violations: MW > 480, WLOGF < -0.4, MR > 130, #atoms > 70 Veber No; 1 violation: TFSA > 13.6 Musegge No; 1 violation: TFSA > 13.6 Musegge No; 4 violations: MW > 600, TFSA > 13.0, H-acc > 10, H-don > 5 Bioavailability score 0.17  Lipinski Yes; 0 violation Ghose Yes Veber Yes Egan Yes Musegge Yes Bioavailability score 0.55  Lipinski No; 3 violations: MW > 600, NorO > 10, NhorOH > 5 Ghose Yes Veber Yes Egan Yes Musege Yes Bioavailability Score 0.55	hERG inhibition high risk Medaka at 3-73921 Minnow at 1.38214 TA100 IORLI negative TA100 NA negative TA1553 IORLI negative TA1553 IORLI negative TA1555 IOR negative TA1555 IOR negative TA1555 IOR negative TA1555 IOR negative TA1555 IORLI negative Carcino Mouse negative Carcino Mouse negative Carcino Mouse negative Daphnia at 2.55255 IERG inhibition ambiguous Medaka at 12.3433 Minnow at 5.4421 TA100 IORLI negative TA1553 IORLI negative TA1553 IORLI negative TA1553 IORLI negative TA1553 IORLI negative TA1555 IORLI negative Carcino Rat positive Daphnia at 0.030538 Minnow at 0.0152727 TA100 IORLI negative TA1553 IORLI negative TA1555 IORLI negative Daphnia at 0.961213 IERG inhibition high risk Medaka at 1.81708 Minnow at 1.91089	No
Citrus reticulata Blanco	Quercetin, 3-o-rutinoside Synonymous Rutin Apigenin	Solubility 2.10e-02 mg/ml. 4.51e-05 mol/l Class  Moderately soluble Log S (SILCOS-IT) -1.51 Solubility 1.43e+01 mg/ml. 3.08e-02 mol/l Class Soluble Log S (ESOL) -3.30 Solubility 3.08e-01 mg/ml. 3.08e-04 mol/l Class Soluble Log S (Ali) -4.87 Solubility 8.30e-03 mg/ml. 1.36e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -0.29 Solubility 3.15e+02 mg/ml. 1.14e-04 mol/l Class Soluble Log S (Ali) -3.94 Solubility 3.07e-02 mg/ml. 1.14e-04 mol/l Class Soluble Log S (ESOL) -3.94 Solubility 3.07e-02 mg/ml. 1.14e-04 mol/l Class Soluble Log S (SILICOS-IT) -4.00 Solubility 1.25e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -4.40 Solubility 3.94e-05 mol/l Class Moderately soluble Log S (SISICOS-IT) -4.40 Solubility 3.94e-05 mol/l Class Solubility 3.94e-05 mol/l Class Solubility 3.19e-01 mg/ml. 3.28e-04 mol/l Class Solubility 3.32e-04 mol/l Class Solubility 3.32e-04 mol/l Class Solubility 3.32e-04 mol/l Class Solubility 3.32e-05 mol/l Class Solubility 4.72e-05 mol/l Class Solubility 4.72e-05 mol/l Class Solubility 4.72e-05 mol/l Class	CYP2C9 inhibitor No CYP2C9 inhibitor No CYP2A6 inhibitor No CYP3A4 inhibitor No Log Kp (skin permeution)  GI absorption Low BBB permeant No P-gs substrate Yes CYP1A2 inhibitor No CYP2C9 inhibitor No CYP3C9 inhibitor No CYP2C9 inhibitor No	Veber No; 1 volation: TPSA > 140 Egan No; 1 volation: TPSA > 131.6 Muegge No; 3 violations: TPSA > 150, H-acc > 10, H-don > 5 Bioavailability score 0.17  Lipinski No; 3 violations: MW > 500, NorO > 10, NHorOH > 5 Ghose No; 4 violation: MW > 480, WLOGP < −0.4, MR > 130, #atoms > 70 Veber No; 1 violation: TPSA > 131.6 Muegge No; 4 violations: MW > 600, TPSA > 130, H-acc > 10, H-don > 5 Bioavailability score 0.17  Lipinski Yes; 0 violation Ghose Yes Veber Yes Egan Yes Muegge Yes Bioavailability Score 0.55  Lipinski No; 3 violations: MW > 500, NorO > 10, NHorOH > 5 Chose No; 4 violation: TPSA > 150, H-acc > 10, H-don > 5 Bioavailability Score 0.55	hRRG inhibition high risk Medala at 3-7921 Minnow at 1.38214 TA100 IORLI negative TA105 NA negative TA105 NRI negative Daphnia at 2.5825 HRG inhibition ambiguous Medala at 12.3433 Minnow at 5.4421 TA100 IORLI negative TA105 NRI negative TA105 NRI negative TA155 IORLI negative TA155 IORLI negative TA155 NRI negative TA155 IORLI negative TA106 IORLI negative TA107 NRI	No
Citrus reticulata Blanco	Quercetin, 3-o-rutinoside Synonymous Rutin Apigenin	Solubility 2.10e-02 mg/ml. 4.51e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -1-51 Solubility 1.43e+01 mg/ml. 3.08e-02 mol/l Class Soluble Log S (ESOL) -3.30 Solubility 3.08e-01 mg/ml. 5.05e-04 mol/l Class Soluble Log S (Ali) -4.87 Solubility 8.30e-03 mg/ml. 1.36e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -0.29 Solubility 3.15e+02 mg/ml. 3.15e-01 mol/l Class Soluble Log S (SILICOS-IT) -0.20 mg/ml. 1.14e-04 mol/l Class Soluble Log S (SILICOS-IT) -0.20 mg/ml. 1.51e-01 mol/l Class Soluble Log S (SILICOS-IT) -4.40 Solubility 3.07e-02 mg/ml. 1.14e-04 mol/l Class Soluble Log S (SILICOS-IT) -4.40 Solubility 3.15e-01 mg/ml. 3.25e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -4.40 Solubility 3.19e-01 mg/ml. 3.24e-05 mol/l Class Soluble Log S (SILICOS-IT) -4.32e-05 mol/l Class Soluble Log S (SILICOS-IT) -4.32e-04 mg/ml. 2.32e-04 mol/l Class Soluble Log S (SILICOS-IT) -4.30 Solubility 3.19e-01 mg/ml. 3.22e-04 mol/l Class Soluble Log S (Ali) -4.31 Solubility 3.19e-01 mg/ml. 3.22e-04 mol/l Class Solubility Class Solubility 2.88e-02 mg/ml. 4.72e-05 mol/l Class Moderately soluble Log S (SILICOS-IT)	CYP2C19 inhibitor No CYP2A5 inhibitor No CYP2A6 inhibitor No CYP2A6 inhibitor No CYP3A6 inhibitor No Log Kp (skin permeation)  —8.88 cm/s  GI absorption Low BBB permeant No P-gg substrate Yes CYP1A2 inhibitor No CYP2A5 inhibitor No CYP2A5 inhibitor No CYP2A6 inhibitor No CYP2A6 inhibitor No CYP3A6 inhibitor No CYP3A6 inhibitor No CYP3A6 inhibitor Yo CYP3A7 inhibitor Yo CYP3A6 inhibitor No	Veber No; 1 violation: TPSA > 140 Egan No; 1 violation: TPSA > 131.6 Muegge No; 3 violations: TPSA > 150, H-acc> 10, H-don > 5 Bioavailability score 0.17  Lipinski No; 3 violations: MW > 500, NorO > 10, NHorOH > 5 Ghose No; 4 violation: MW > 480, WLOGP < −0.4, MR > 130, #atoms > 70 Veber No; 1 violation: TPSA > 131.6 Muegge No; 4 violations: MW > 600, TPSA > 130, H-acc> 10, H-don > 5 Bioavailability score 0.17  Lipinski Yes; 0 violation Ghose Yes Veber Yes Egan Yes Muegge Yes Bioavailability Score 0.55  Lipinski No; 3 violations: MW > 500, NorO > 10, NHorOH > 5 Ghose No; 4 violation: TPSA > 130, #atoms > 70 Veber No; 1 violation: TPSA > 140 Egan No; 1 violation: TPSA > 140 Egan No; 1 violation: TPSA > 130, #atoms > 70 Veber No; 4 violation: TPSA > 130, #atoms > 70 Veber No; 4 violation: TPSA > 131.6 Muegge No; 4 violation: TPSA > 131.6 Muegge No; 4 violations: MW > 600, TPSA > 131.6	hERG inhibition high risk Medaka at 3-73921 Minnow at 1.38214 TA100 IORLI negative TA100 NA negative TA105 NA negative TA1555 IORLI negative Carcino Rat negative Daphnia at 2.55255 IERG inhibition ambiguous Medaka at 12.3433 Minnow at 5.4421 TA100 IORLI negative TA105 IORLI positive TA106 IORLI negative TA1555 IORLI negative Daphnia at 0.961215 IERG inhibition high risk Medaka at 1.81708 Minnow at 1.91089 TA100 IORLI negative	No
Citrus reticulata Blanco	Quercetin, 3-o-rutinoside Synonymous Rutin Apigenin	Solubility 2.10e-02 mg/ml. 4.51e-05 mol/l Class  Moderately soluble Log S (SILCOS-IT) -1.51 Solubility 1.43e+01 mg/ml. 3.08e-02 mol/l Class Soluble Log S (ESOL) -3.30 Solubility 3.08e-01 mg/ml. 3.08e-04 mol/l Class Soluble Log S (Ali) -4.87 Solubility 8.30e-03 mg/ml. 1.36e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -0.29 Solubility 3.15e+02 mg/ml. 1.14e-04 mol/l Class Soluble Log S (Ali) -3.94 Solubility 3.07e-02 mg/ml. 1.14e-04 mol/l Class Soluble Log S (ESOL) -3.94 Solubility 3.07e-02 mg/ml. 1.14e-04 mol/l Class Soluble Log S (SILICOS-IT) -4.00 Solubility 1.25e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -4.40 Solubility 3.94e-05 mol/l Class Moderately soluble Log S (SISICOS-IT) -4.40 Solubility 3.94e-05 mol/l Class Solubility 3.94e-05 mol/l Class Solubility 3.19e-01 mg/ml. 3.28e-04 mol/l Class Solubility 3.32e-04 mol/l Class Solubility 3.32e-04 mol/l Class Solubility 3.32e-04 mol/l Class Solubility 3.32e-05 mol/l Class Solubility 4.72e-05 mol/l Class Solubility 4.72e-05 mol/l Class Solubility 4.72e-05 mol/l Class	CYP2C9 inhibitor No CYP2C9 inhibitor No CYP2A6 inhibitor No CYP3A4 inhibitor No Log Kp (skin permeution)  GI absorption Low BBB permeant No P-gs substrate Yes CYP1A2 inhibitor No CYP2C9 inhibitor No CYP3C9 inhibitor No CYP2C9 inhibitor No	Veber No; 1 volation: TFSA > 140 Egan No; 1 volation: TFSA > 131.6 Musegge No; 3 violations: TFSA > 150, H-acc > 10, H-don > 5 Bioavailability score 0.17  Lipinski No; 3 violations: MW > 500, NorO > 10, NHorOH > 5 Ghose No; 4 violation: MW > 480, WLOGF < -0.4, MR > 130, #atoms > 70 Veber No; 1 violation: TFSA > 140 Egan No; 1 violation: TFSA > 131.6 Musegge No; 4 violations: MW > 600, TFSA > 150, H-acc > 10, H-don > 5 Bioavailability score 0.17  Lipinski Yes; 0 violation Ghose Yes Veber Yes Egan Yes Musegge Yes Bioavailability score 0.55  Lipinski No; 3 violations: MW > 600, TFSA > 150, H-acc > 10, H-don > 5 Bioavailability score 0.17  Lipinski Yes; 0 violation Ghose Yes Veber Yes Egan Yes Musegge Yes Bioavailability Score 0.55  No; 4 violations: MW > 80, WLOGF < -0.4, MR > 130, #atoms > 70 Veber No; 1 violation: TFSA > 140 Egan No; 1 violation: TFSA > 141.6 Musegge	hRRG inhibition high risk Medala at 3-7921 Minnow at 1.38214 TA100 IORLI negative TA105 NA negative TA105 NRI negative Daphnia at 2.5825 HRG inhibition ambiguous Medala at 12.3433 Minnow at 5.4421 TA100 IORLI negative TA105 NRI negative TA105 NRI negative TA155 IORLI negative TA155 IORLI negative TA155 NRI negative TA155 IORLI negative TA106 IORLI negative TA107 NRI	No
Citrus reticulata Blanco	Quercetin, 3-o-rutinoside Synonymous Rutin Apigenin	Solubility 2.10e-02 mg/ml. 4.51e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -1.51 Solubility 1.43e+01 mg/ml. 3.08e-02 mol/l Class Soluble Log S (ESOL) -3.30 Solubility 3.08e-01 mg/ml. 5.08e-04 mol/l Class Soluble Log S (Ali) -4.87 Solubility 8.30e-03 mg/ml. 1.36e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -0.29 Solubility 3.15e+02 mg/ml. 5.15e-01 mol/l Class Soluble Log S (Ali) -4.87 Solubility 8.30e-02 mg/ml. 1.14e-04 mol/l Class Moderately soluble Log S (SILICOS-IT) -0.29 Solubility 3.17e+02 mg/ml. 3.15e-01 mol/l Class Soluble Log S (SILICOS-IT) -3.19e-01 mg/ml. 3.34e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -4.40 Solubility 3.07e-02 mg/ml. 3.44e-05 mol/l Class Moderately soluble Log S (SILICOS-IT) -4.40 Solubility 3.19e-01 mg/ml. 5.32e-04 mol/l Class Moderately soluble Log S (SILICOS-IT) -3.28 Solubility 3.19e-01 mg/ml. 5.32e-05 mol/l Class Soluble Log S (CISICOS-IT) -3.28 Soluble Log S (CISICOS-IT) -3.28 Solubility 3.19e-01 mg/ml. 5.23e-05 mol/l Class Soluble Log S (CISICOS-IT) -3.28 Solublity 3.19e-01 mg/ml. 5.22e-05 mol/l Class Solublity 4.20e-05 mg/ml. 4.72e-05 mol/l Class Solublity 4.20e-07 mg/ml. 5.22e-05 mol/l Class Solublity 4.20e-07 mg/ml. 5.22e-05 mol/l Class Solublity 4.20e-07 mg/ml. 5.22e-05 mol/l Class Solublity 4.20e-07 mg/ml. 5.22e-07	CYP2C19 inhibitor No CYP2A5 inhibitor No CYP2A6 inhibitor No CYP2A6 inhibitor No CYP3A6 inhibitor No Log Kp (skin permeation)  —8.88 cm/s  GI absorption Low BBB permeant No P-gg substrate Yes CYP1A2 inhibitor No CYP2A5 inhibitor No CYP2A5 inhibitor No CYP2A6 inhibitor No CYP2A6 inhibitor No CYP3A6 inhibitor No CYP3A6 inhibitor No CYP3A6 inhibitor Yo CYP3A7 inhibitor Yo CYP3A6 inhibitor No	Veber No; 1 violation: TPSA > 140 Egan No; 1 violation: TPSA > 131.6 Muegge No; 3 violations: TPSA > 150, H-acc> 10, H-don > 5 Bioavailability score 0.17  Lipinski No; 3 violations: MW > 500, NorO > 10, NHorOH > 5 Ghose No; 4 violation: MW > 480, WLOGP < −0.4, MR > 130, #atoms > 70 Veber No; 1 violation: TPSA > 131.6 Muegge No; 4 violations: MW > 600, TPSA > 130, H-acc> 10, H-don > 5 Bioavailability score 0.17  Lipinski Yes; 0 violation Ghose Yes Veber Yes Egan Yes Muegge Yes Bioavailability Score 0.55  Lipinski No; 3 violations: MW > 500, NorO > 10, NHorOH > 5 Ghose No; 4 violation: TPSA > 130, #atoms > 70 Veber No; 1 violation: TPSA > 140 Egan No; 1 violation: TPSA > 140 Egan No; 1 violation: TPSA > 130, #atoms > 70 Veber No; 4 violation: TPSA > 130, #atoms > 70 Veber No; 4 violation: TPSA > 131.6 Muegge No; 4 violation: TPSA > 131.6 Muegge No; 4 violations: MW > 600, TPSA > 131.6	hRRG inhibition high risk Medala at 3-7921 Minnow at 1.38214 TA100 IORLI negative TA105 NA negative Daphnia at 2.5825 hRG inhibition ambiguous TA100 NA negative TA100 NA negative TA105 NA negative TA106 IORLI negative TA106 IORLI negative TA107 NA positive TA107 NA positive TA108 NA positive TA108 NA positive TA108 NA positive TA108 NA negative TA109 NA INFORMATION NA NA NEGATIVE Algae at 0.00697422 Ames test non-mutagen Carcino Mouse negative TA106 IORLI negative TA107 NA negative TA108 NA negative TA108 NA negative TA109 NA negative TA109 NA negative TA100 NA negative	No

Table 9: Continued.

Log S (ESOL)	Toxicity	
-3.78 Solubility 7.19e - 02 mg/m; 1.66e - 04 mol/l Class GI absorption Low Lipinski Soluble BBB permean No Yes; 1 violation: NHorOH > 5 Log S (Ail) P-gs substrate Yes Ghose Yes -5.00 CYP1A2 inhibitor No Veber Cosmetin Solubility CYP2C19 inhibitor No No; 1 violation: TPSA > 140 L32e - 03 mg/ml; 9.99e - 06 mol/l Class CYP2C9 inhibitor No No; 1 violation: TPSA > 131.6		Eligibility
Solubility		
7.19e − 02 mg/ml; 166e − 04 mol/l   Class GI absorption Low Lipinski   Soluble BBB permean No Yes; 1 violation: NHorOH > 5   Log S (Aii) Pg. substrate Yes Ghose Yes   -5.00 CYP1A2 inhibitor No Veber   Solubility CYP2C19 inhibitor No No; 1 violation: TPSA > 140   Cosmetin 4.32e − 03 mg/ml; 999e − 06 mol/l CYP2C9 inhibitor No Egan   Class CYP2C9 inhibitor No No; 1 violation: TPSA > 131.6		
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Algae at 0.0230381	
Log S (Ali)   P-gs substrate Yes   Ghose Yes	Ames test mutagen	
-5.00 CYP1A2 inhibitor No Veber  Solubility CYP2.C9 inhibitor No No; 1 violation: TPSA > 140  Cosmetin 4.32e - 0.3 mg/ml; 9.99e - 0.6 mol/1 CYP2.C9 inhibitor No Egan  Class CYP2.D6 inhibitor No No; 1 violation: TPSA > 131.6	Carcino Mouse positive Carcino Rat negative	
Cosmetin	Daphnia at 0.5109	
4.52e - 0.5 mg/m; Vg 0.6 mol/l C172.50 minbitor No Egan C1828 CVP2D6 inhibitor No No; 1 violation: TPSA > 131.6	hERG inhibition high risk	No
	Medaka at 0.46598 Minnow at 0.447713	
	TA100 10RLI negative	
Log S (SILICOS-IT) Log Kp (skin permeation) No; 2 violations: TPSA > 150, H-don > 5	TA100 NA negative	
-2.69 -7.65 cm/s Bioavailability Score 0.55 Solubility	TA1535 10RLI negative TA1535 NA negative	
8.77e – 01 mg/ml; 2.03e – 03 mol/l	1A1555 NA Hegative	
Class		
Soluble		
Solubility	Algae at 0.0368839	
$8.46e - 02 \mathrm{mg/ml}$ ; $2.80e - 04 \mathrm{mol/l}$ GI absorption High	Ames test mutagen Carcino Mouse negative	
Class BBB permeant No Lipinski Yes; 0 violation Soluble P <sub>2</sub> -p <sub>3</sub> substrate No	Carcino Rat positive	
Log S (Ali) 4.56 CVPIA2 inhibitor Vac	Daphnia at 0.206834	
Herbacetin Solubility 8.29e – 03 mg/ml; 2.74e – 05 mol/l CYP2C19 inhibitor No Fear Ves	hERG inhibition medium risk Medaka at 0.0728344	No
Clas CYPC9 inhibitor No Magage Yes  Moderately soluble CYP216 inhibitor Yes Magage Yes	Minnow at 0.0352894	
Signatures source  Log S (SILICOS-IT) - 3.24 CYP3A4 inhibitor Yes  Bioavailability score 0.55	TA100 10RLI negative	
Solubility 1.73e – 01 mg/ml; 5.73e – 04 mol/1 Log Kp (skin permeation) – 6.60 cm/s	TA100 NA positive TA1535 10RLI negative	
Class	TA1535 NA negative	
Soluble Log S (ESOL)	-	
-3.28		
Solubility Lipinski	Algae at 0.00697422	
S.19e-O inging: 3.25e-O simori Gi assorption tow No; 3 violations: MW>500, NorO>10, NHorOH>5	Ames test non-mutagen Carcino Mouse negative	
Soluble P-gp substrate Yes Gnose	Carcino Rat negative	
Log S (Ali) CYP1A2 inhibitor No Valor Vocations: www sates, www.rest, with sates, www.rest, www.	Daphnia at 0.961213	
Hesperidin (duplicated) 4-33 CYP2C19 inhibitor No No; 1 violation: TPSA > 140 Solubility CYP2C9 inhibitor No.	hERG inhibition high risk Medaka at 1.81708	No
Southing CTP2.9 million to No Egan	Minnow at 1.91089	
Log S (SILICOS-IT) CYP3A4 inhibitor No No; I violation: TPSA 131.6	TA100 10RLI negative	
-0.58 Log Kp (skin permeation) Soublility -1.012 cm/s No; 4 violations: MW > 600, TFSA > 150, H -acc > 10, H -don > 5	TA100 NA negative TA1535 10RLI negative	
Sombuly $-10.12\mathrm{cm/s}$ Bioavailability score $0.17$ $1.60e+02\mathrm{mg/m}$ , $2.62e-01\mathrm{mol/l}$	TA1535 10KLI negative	
Class		
Soluble		
Log S (ESOL) – 3.31 Solubility 1.40e – 01 mg/ml; 4.90e – 04 mol/1	Algae at 0.0483223 Ames test mutagen	
Somminy 1-vec - or linguin, 4-yec - or intur. Gl absorption High Class BB permean No	Carcino Mouse negative	
Soluble P-om substrate No. Lipinski Yes; 0 violation	Carcino Rat positive	
Epineara sinica Stapy  Log S (All)3.89  CYPIA2 inhibitor Yes  Uniose res  CYPIA2 inhibitor Yes	Daphnia at 0.196882 hERG inhibition medium risk	
Kaempterol Closs CYP2C19 inhibitor No Eggn Yes	Medaka at 0.0642539	No
Soluble CYPEOS infinition No Muegge Yes	Minnow at 0.0294885	
Log S (SILICOS-IT) -3.82 Bioavailability score 0.55	TA100 10RLI negative	
Solubility 4.29e – 02 mg/ml ; 1.50e – 04 mol/l Class Log Kp (disp repmetton) – 6.70 cm/s	TA100 NA positive TA1535 10RLI negative	
Soluble	TA1535 NA negative	
Log S (ESOL) –3.71	Algae at 0.0416314	
Solubility 5.63e – 02 mg/ml. 197e – 04 mol/l GI absorption High	Ames test mutagen Carcino Mouse negative	
Soluble Lipinski Yes; 0 violation	Carcino Rat positive	
Log S (All) = 4-51	Daphnia at 0.139325	
Luteolin Solubility 8.84e – 03 mg/mi; 3.09e – 05 mol/1 CYP2C19 inhibitor No Fean Ves	hERG inhibition medium risk Medaka at 0.0329883	No
Moderately soluble CYPCO9 inhibitor Yos Muegge Yes	Minnow at 0.0169052	
Log S (SILICOS-11) -3.82 Bioavailability score 0.55	TA100 10RLI negative	
Solubility 4.29e – 20 mg/li. 150e – 04 mg/li Class Log Kp (skin permentation) – 6.25 cm/s	TA100 NA positive TA1535 10RLI negative	
Soluble	TA1535 NA negative	
Log S (ESOL)		
-3-30 Solubility		
3.08e – 01 mg/ml; 5.05e – 04 mol/l GI absorption Low Lipinski	Algae at 0.0069585 Ames test non-mutagen	
Class PRP permant No. No; 3 violations: MW > 500, NorO > 10, NHorOH > 5	Carcino Mouse negative	
Solube P-gp substrate Yes Gnose	Carcino Rat negative	
Log 3 (vii) CYPIA2 inhibitor No No; 4 violations: AVV >460, WLAGE <-0.4, MR >150, 4 atomis > 70  4-87 CEPTON 0.4-4-16-16-16-17  CEPTON 0.4-4-16-16-16-17  CEPTON 0.4-4-16-16-16-17  CEPTON 0.4-4-16-16-16-16-16-16-16-16-16-16-16-16-16-	Daphnia at 2.55255	
Rutin (duplicated) Solubility CYPZCI9 inhibitor No No; 1 violation: TPSA > 140  CYPZCI9 inhibitor No No; 1 violation: TPSA > 140	hERG inhibition ambiguous Medaka at 12.3433	No
8.90e – 0.5 mg/ml; 1.56e – 0.5 mg/l CYP2D6 inhibitor No Liquidition TPXA \ 131.6	Minnow at 5.4421	
Log S (SILICOS.IT) CYP3A4 inhibitor No Muggge	TA100 10RLI negative	
-0.29 Log Np (san permeanon) -0.29 No; 4 violations: MW > 600, TPSA > 150, H-acc > 10, H-don > 5	TA100 NA negative TA1535 10RLI negative	
Solubility	TA1535 NA negative	
3.15e + 0.2 mgm; 3.15e - 01 mour Class		
Soluble		
Log S (ESOL) -2-2-84		
-2.0°I	Algae at 0.0287951	
Solution C 20 - 01	Ames test non-mutagen Carcino Mouse positive	
Solubility 6.29e – 01 mg/ml; 1.46e – 03 mol/1  Gl absorption Low  Class soluble  The control of	Carcino Rat negative	
Solubility 6.29e – 01 mg/ml. 1.46e- 03 mg/dl. 4.16e- 03 mg/dl. Gl absorption Low Yes; 1 violation NHorOH > 5 Log S (All) P-gs substrate No Ghose	Daphnia at 0.775983	
Solubility 6.29e - 01 mg/ml; 1.46e - 03 mol/1	hERG inhibition high risk Medaka at 1.05813	No
Solubility 6.29e - 01 mg/ml; 1.46e - 03 mol/1	Minnow at 0.763184	
Solubility 6.29e - 01 mg/ml. 1.46e - 03 mol/1	TA100 10RLI negative	
Solubility 6.29e - 01 mg/ml; 1.46e - 03 mol/l		
Solubility 6.29e - 01 mg/ml; 1.46e - 03 mol/l   GI absorption Low   Lipinski	TA100 NA negative	
Solubility 6.29e - 01 mg/ml. 1.46e - 03 mol/l   GI absorption Low   Lipinski	TA100 NA negative TA1535 10RLI negative TA1535 NA negative	
Solubility 6.29e - 01 mg/ml; 1.46e - 03 mol/1	TA1535 10RLI negative	
Solubility 6.29e - 00 mg/ml. 1.46e - 03 mol/l 1.46e - 0	TA1535 10RLI negative	
Solubility 6.29e - 01 mg/ml; 1.46e - 03 mol/l   Gil absorption Low   Lipinaki	TA1535 10RLI negative TA1535 NA negative Algae at 0.0653294	
Solubility 6.29e - 01 mg/ml; 1.46e - 03 mol/1	TA1535 10RLI negative TA1535 NA negative Algae at 0.0653294 Ames test mutagen	
Solubility 6.29e - 01 mg/ml; 1.46e - 03 mol/1	TA1535 10RLI negative TA1535 NA negative  Algae at 0.0653294 Ames test mutagen Carcino Mouse negative	
Solubility 6.29e - 01 mg/ml; 1.46e - 03 mol/1	TA1535 10RLI negative TA1535 NA negative  Algae at 0.0653294  Ames test mutagen Carcino Mouse negative Carcino Rat positive Daphnia at 0.142765	
Solubility 6.29e - 01 mg/ml. 1.46e - 03 mol/l   Gil absorption Low   Lipinski	TA1535 10RLI negative TA1535 NA negative Algae at 0.0653294 Ames test mutagen Carcino Mouse negative Carcino Rat positive Daphnia at 0.142765 hERG inhibition medium risk	No
Solubility 6.29e - 01 mg/ml. 1.46e - 03 mol/l   Class soluble   BBB permeant No   Yes; 1 violation: NHorOH > 5     Log S (All)   Pg substrate No   Chose     -3.57   CYP1A2 inhibitor No   Yes     Vitexin   1.16e - 01 mg/ml. 2.68e - 04 mol/l   CyP2(9) inhibitor No   Veber     Class soluble   CYP2(9) inhibitor No   No. 1 violation: TPSA > 140     Class soluble   CYP2(9) inhibitor No   No. 1 violation: TPSA > 140     Class soluble   CYP2(9) inhibitor No   No. 1 violation: TPSA > 131,6     Class soluble   CYP2(9) inhibitor No   No. 1 violation: TPSA > 131,6     Class   Class   CYP3A4 inhibitor No   No. 1 violation: TPSA > 131,6     Class   Class   CyP3A4 inhibitor No   No. 2 violations: TPSA > 130, H-don > 5     Class   Class   Class   CyP3A4 inhibitor No   No. 2 violations: TPSA > 150, H-don > 5     Class   Class   CyP3A4 inhibitor No   No. 2 violations: TPSA > 150, H-don > 5     Class   Class   CyP3A4 inhibitor No   CyP3A44 inhib	TA1535 10RL1 negative TA1535 NA negative Algae at 0.0653294 Ames test mutagen Carcino Mouse negative Carcino Rat positive Daphnia at 0.142765 hERG inhibition medium risk Medaka at 0.0311152	No
Solubility 6.29e - 01 mg/ml. 14e- 03 mol/l   GI absorption Low   Lipinski	TA1535 10RLI negative TA1535 NA negative Algae at 0.0653294 Ames test mutagen Carcino Mouse negative Carcino Rat positive Daphnia at 0.142765 hERG inhibition medium risk	No
Solubility 6.29c - 01 mg/ml. 1.46c - 03 mol/l Class soluble   Lag c (Ali)   RBB permeant No   Choose   Comparison   Comp	TA1535 10RL1 negative TA1535 NA negative TA1535 NA negative Aligae at 0.0653294 Arnes test mutagen Carcino Mouse negative Carcino Rat positive Daphnia at 0.142765 BERG inhibition medium risk Medaka at 0.0311152 Minnow at 0.0148234 TA100 10RL1 positive TA100 NA positive TA100 NA positive	No
Solubility 6.29e - 01 mg/ml; 1.46e - 03 mol/l   Gil absorption Low   Lipinski   Lipinski   Class soluble   BBB permean No   Yes; 1 violation: NHorOH > 5   Choose	TA1535 10RL1 negative TA1535 NA negative Algae at 0.0653294 Annes test mutagen Carcino Mouse negative Carcino Rat positive Daphnia at 0.142765 hERG inhibition medium risk Medaka at 0.0311152 Minnow at 0.0148244 TA100 10RL1 positive	No




FIGURE 3: The simulation of atractylenolide III with ACE2 and 2-dimensional diagram.

displayed as a "licorice" 3D structure. The key residues on ACE2 predicted to be involved in interaction with the ligand are also shown and involve a conventional hydrogen bond via ASN-149 (green) and pi-alkyl interaction via PHE 274 (yellow). As the binding results from hydrogen bond (H-bond) in chain B (Table 3) showed that SER254 can form a H-bond with SARS-CoV-2 spike glycoprotein. The binding results from hydrogen bond in chain C (Table 6) showed that ASP157, ASN159, TYR252 on ACE2 can form the H-bonds with SARS-CoV-2 spike glycoprotein. The ligand therefore binds in a region that shares a similar face as the ACE2 residues which are predicted to form contact with the SARS-CoV-2 spike glycoprotein. The ligand may

therefore serve to disrupt, or weaken, ACE2-mediated virus-host cell interactions acting via this surface. A 2-dimensional diagram showed that the ASN 149 binding site in ACE2 is connected with a hydroxyl group in the molecule.

### 4. Discussion

The novel SARS-CoV-2 virus emerged to challenge the current medical system, exposing the shortfalls of existing pharmaceutical agents for its management. The Chinese Health Commission included Chinese herbal medicine amongst its current recommendations for disease

management and have prescribed herbal formulas from its 4<sup>th</sup> edition of SARS-CoV-2 virus management guidelines. In the initial stage, 9 herbs were prescribed for treating the symptoms, including chills, dry cough, dry throat, drowsiness, and chest tightness. Except Amomum tsaoko Crevost et Lemarie (Caoguo) and Areca catechu L. (Binglang), the other 7 herbs are among the highfrequency Chinese medicines for the management of pestilence throughout the history in China [19]. ACE2 receptors are viewed as the key protein in human for the development of SARS-CoV-induced lung injury [6]. Molecular docking was used to predict the binding mechanisms of both SARS-CoV-2 and SARS-CoV spike glycoproteins to ACE2, and it was identified that residue 487 for both viral proteins played a role in their binding to ACE2. The residue at position 487 for both SARS-CoV-2 and SARS-CoV spike glycoproteins has been proposed to be crucial for cross-species and human transmission for SARS-CoV [20]. Our results have echoed the findings from previous research that may strengthen the understanding of a similar role for the residue at this position of the new virus. Despite this similarity, there is still a large discrepancy between these two viruses in terms of binding chains and binding sites. These differences may be contributed by their genomic sequence diversity [20]. The binding results showed that SARS-CoV-2 could have two chains binding with ACE2 receptor rather than SARS-CoV with one chain binding with ACE2. More chain bindings or interactions and more energy consumptions indicate much stronger binding affinity for this new virus [21, 22]. The simulation predicted that chain C for both viruses is critical for the binding activities with ACE2. For SARS-CoV-2, the residues in chain C are LYS 417, GLU 484, ASN 487, TYR 489, GLN 493, and TYR 505. From the findings in another in silico study with the same PDB ID (6ACG) protein for modelling, the residue in position 505 (-4.23 kcal/mol) plays an important role for spike glycoprotein of SARS-CoV-2 in terms of the binding energy contribution in comparison with the residues in position 487 (-1.5 kcal/mol) and 489 (-3.0 kcal/mol) [22]. From another in silico study, the amino acid residues ASN157, ASN159, and SER 280 have contributed to the solvent at the surface of the ACE2 molecule (PDB ID:1RIX) in the binding with SARS-CoV spike glycoproteins [23].

Molecular docking and pharmacokinetic screening were also used to identify atractylenolide III, from Atractylodes lancea (Thunb.) Dc. (Cangzhu) as a therapeutic agent with strong binding affinity with ACE2, which also satisfy selection criteria based on pharmacokinetic properties. The key predicted binding site residues on ACE2 are ASN 149, which form a conventional hydrogen bond by one hydroxyl group in the molecule and ASN 149 in ACE2. The results from in vitro inhibition assay showed atractylenolide III with antiviral activity instead of the same analog testing compounds atractylenolide I and atractylenolide II. Since the hydroxyl group is the structural difference between atractylenolide III and the same analog compounds, it can be deduced that the hydroxyl group may play a key role in the inhibition effect

against porcine reproductive and respiratory syndrome virus [10]. The existing evidence could support the therapeutic potential of atractylenolide III for its antiinflammatory activity, anti-porcine reproductive and respiratory syndrome virus activity, and heavy lung tissue distribution. Atractylenolide III (50 µM and 100 µM) possessed anti-inflammatory effects associated with the inhibition of nuclear factor-κB (NF-κB) and mitogenactivated protein kinases- (MAPK-) signaling pathways in lipopolysaccharide- (LPS-) induced RAW264.7 cells via suppression of the production of nitric oxide (NO), prostaglandin E2 (PGE2), tumour necrosis factor-alpha (TNF- $\alpha$ ), and interleukin 6 (IL-6) [24]. Intriguingly, atractylenolide III has been shown to possess inhibitory effects against porcine reproductive and respiratory syndrome virus, which is of importance in the swine industry. This virus can cause similar symptoms of SARS-CoV-2 respiratory infection including fever, cough, and dyspnea. The 50% inhibited concentration (IC50) was 99.6 µmol/L for this compound [10]. Atractylenolide III had been found to have high concentration level in the lung tissues of rats in pharmacokinetics and tissue distribution experiments [25]. It may shed light on the therapeutic potential of this compound for new virusinduced respiratory infections and inflammations. Despite the fact that our findings suggested other compounds with antirespiratory viral activity, the pharmacokinetic properties of these compounds are not eligible to be used as drug candidates. Therefore, atractylenolide III is the sole compound with antirespiratory activity and eligible pharmacokinetic properties to be considered as a drug candidate in our study. This finding is based on in silico study with limited evidence. It is noteworthy that there is no existing evidence from clinical studies to prove the efficacy of this formula. In order to acquire more solid evidential support, further in vitro and in vivo studies are required. The safety of Chinese herbal medicine is often a concern for its application and marketing. From the Chinese Pharmacopoeia 2015 edition, for the formula in the study, most of the herbs are safe to be applied but Citrus reticulata Blanco (dried tangerine peel; Chenpi), Ephedra sinica Stapf (ephedra; Mahuang), and Areca catechu L. (areca seed; Binglang) contain toxic substances. Aflatoxin can be found in both Citrus reticulata Blanco (dried tangerine peel; Chenpi) and Areca catechu L. (areca seed; Binglang). There are strict restrictions for aflatoxin in these herbs. For both Citrus reticulata Blanco (dried tangerine peel; Chenpi) and Areca catechu L. (areca seed; Binglang), Aflatoxin B1 cannot exceed  $5 \mu g$  per 1000 grams. Also, the total amount of aflatoxin G1, aflatoxin G2, aflatoxin B1, and aflatoxin B2 cannot be more than 10 µg. The toxic compound ephedrine in Ephedra sinica Stapf (ephedra; Mahuang) may raise the biggest concerns among all the herbs in the formula. A series of toxic events and adverse effects had been reported that included arrhythmia, hepatotoxicity, cardiovascular toxicity, and dilated pupils after application of ephedra. Despite such safety concerns, the safe application of

ephedra can be safeguarded by different processing techniques [26].

In conclusion, SARS-CoV-2 could bind with the ACE2 receptor at chain B and chain C to induce lung injuries in humans. The residue at position 487 may play a vital role as it did on SARS-CoV for the progression of lung injuries. Atractylenolide III is found to have a strong binding affinity with ACE2 by conventional hydrogen bond formation via ASN-149 and possess favourable pharmacokinetic properties, and it has been shown to exhibit anti-inflammatory effects and antiviral effects in a previous *in vitro* study and high distribution in the lungs in a previous *in vivo* study. All these findings support further research for the therapeutic effects of atractylenolide III for the management of this new virus.

## **Abbreviations**

ACE2: Angiotensin-converting enzyme 2

ADME: Absorption, distribution, metabolism, and

excretion

H-bond: Hydrogen bond
IL-6: Interleukin 6
LPS: Lipopolysaccharide

MAPK: Mitogen-activated protein kinases

MERS- Middle East respiratory syndrome coronavirus

CoV:

NF-κB: Nuclear factor-κB NO: Nitric oxide PGE2: Prostaglandin E2

SARS- Severe acute respiratory syndrome coronavirus

Cov:

TNF-α: Tumour necrosis factor-alpha WHO: World Health Organization.

### **Data Availability**

The data are available upon request to the corresponding author.

### **Conflicts of Interest**

The authors declare that they have no conflicts of interest.

### **Authors' Contributions**

Y. S. participated in information collection, computational analysis, and drafting. A. W. H. Y. and A. H. were responsible for writing, review, and editing. G. B. L. performed review and supervision. All authors read and approved the final manuscript.

# Acknowledgments

The authors thank the medical workers and researchers who are dedicating their strength and knowledge for the control of this virus outbreak in China and other nations.

# **Supplementary Materials**

The supplementary files and tables are available in the separate files. (Supplementary Materials)

#### References

- [1] Y. Chen, Q. Liu, and D. Guo, "Emerging coronaviruses: genome structure, replication, and pathogenesis," *Journal of Medical Virology*, vol. 92, no. 4, p. 418, 2020.
- [2] L. E. Gralinski and V. D. Menachery, "Return of the coronavirus: 2019-nCoV," *Viruses*, vol. 12, no. 2, p. 135, 2020.
- [3] C. Huang, Y. Wang, X. Li et al., "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China," *Lancet*, vol. 12, 2020.
- [4] WHO, Coronavirus Disease 2019 (COVID-19) Situation Report-180, WHO, Geneva, Switerzland, 2020.
- [5] F. K. Mohammad, N. Nusrat, B. R. Ridwan, and C. Akhtaruzzaman, "Computational investigations of physicochemical, pharmacokinetic, toxicological properties and molecular docking of betulinic acid, a constituent of Corypha taliera (Roxb.) with Phospholipase A2 (PLA2)," BMC Complementary and Alternative Medicine, vol. 3, pp. 1–15, 2018.
- [6] K. Kuba, Y. Imai, S. Rao et al., "A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury," *Nature Medicine*, vol. 11, no. 8, pp. 875–879, 2006.
- [7] J. Ru, P. Li, J. Wang et al., "TCMSP: a database of systems pharmacology for drug discovery from herbal medicines," *Journal of Cheminformatics*, vol. 6, no. 1, p. 13, 2014.
- [8] C. A. Bergström and P. Larsson, "Computational prediction of drug solubility in water-based systems: qualitative and quantitative approaches used in the current drug discovery and development setting," *International Journal of Pharma*ceutics, vol. 540, no. 1-2, pp. 185–193, 2018.
- [9] O. Trott and A. J. Olson, "AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading," *Journal of Computational Chemistry*, vol. 31, no. 2, pp. 455–461, 2010.
- [10] W.-G. Li, F.-Y. Dai, Y.-X. Cheng, G.-F Yin, J.-L. Bi, and D.-P. Li, "Identification of porcine reproductive and respiratory syndrome virus inhibitors through an oriented screening on natural products," *Chemical Research in Chinese Universities*, vol. 29, no. 2, pp. 290–293, 2013.
- [11] S. Das, S. Sarmah, S. Lyndem, and A. Singha Roy, "An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study," *Journal of Biomolecular Structure and Dynamics*, vol. 92, pp. 1–11, 2020.
- [12] R. S. Joshi, S. S. Jagdale, S. B. Bansode et al., "Discovery of potential multi-target-directed ligands by targeting hostspecific SARS-CoV-2 structurally conserved main protease," *Journal of Biomolecular Structure and Dynamics*, vol. 92, pp. 1–16, 2020.
- [13] C. Zhang, J. M. Lee, N.-R. Lee, D.-E. Kim, Y.-J. Jeong, and Y. Chong, "Investigation of the pharmacophore space of Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) NTPase/helicase by dihydroxychromone derivatives," *Bioorganic & Medicinal Chemistry Letters*, vol. 19, no. 16, pp. 4538–4541, 2009.
- [14] H. J. Jeong, Y. B. Ryu, S.-J. Park et al., "Neuraminidase inhibitory activities of flavonols isolated from Rhodiola rosea roots and their in vitro anti-influenza viral activities,"

- Bioorganic & Medicinal Chemistry, vol. 17, no. 19, pp. 6816–6823, 2009.
- [15] Y. B. Ryu, H. J. Jeong, J. H. Kim et al., "Biflavonoids from Torreya nucifera displaying SARS-CoV 3CLpro inhibition," *Bioorganic & Medicinal Chemistry*, vol. 18, no. 22, pp. 7940–7947, 2010.
- [16] A.-L. Liu, H.-D. Wang, S. M. Lee, Y.-T. Wang, and G.-H. Du, "Structure-activity relationship of flavonoids as influenza virus neuraminidase inhibitors and their in vitro anti-viral activities," *Bioorganic & Medicinal Chemistry*, vol. 16, no. 15, pp. 7141–7147, 2008.
- [17] M. Thapa, Y. Kim, J. Desper, K.-O. Chang, and D. H. Hua, "Synthesis and antiviral activity of substituted quercetins," *Bioorganic & Medicinal Chemistry Letters*, vol. 22, no. 1, pp. 353–356, 2012.
- [18] T. T. Dao, T. T. Dang, P. H. Nguyen, E. Kim, P. T. Thuong, and W. K. Oh, "Xanthones from Polygala karensium inhibit neuraminidases from influenza A viruses," *Bioorganic & Medicinal Chemistry Letters*, vol. 22, no. 11, pp. 3688–3692, 2012.
- [19] X. Ren, X.-X. Shao, X.-X. Li et al., "Identifying potential treatments of COVID-19 from Traditional Chinese Medicine (TCM) by using a data-driven approach," *Journal of Ethnopharmacology*, vol. 1, 2020.
- [20] X. Xu, P. Chen, J. Wang et al., "Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission," *Science China Life Sciences*, vol. 3, pp. 1–4, 2020.
- [21] B. Lone and M. Lone, "The binding mechanism of coronavirus disease 2019 with human angiotensin converting enzyme 2," 2020.
- [22] C. Peng, Z. Zhu, Y. Shi et al., "Exploring the binding mechanism and accessible angle of SARS-CoV-2 spike and ACE2 by molecular dynamics simulation and free energy calculation," 2020.
- [23] P. Prabakaran, X. Xiao, and D. S. Dimitrov, "A model of the ACE2 structure and function as a SARS-CoV receptor," *Biochemical and Biophysical Research Communications*, vol. 314, no. 1, pp. 235–241, 2004.
- [24] G.-Q. Ji, R.-Q. Chen, and L. Wang, "Anti-inflammatory activity of atractylenolide III through inhibition of nuclear factor-κB and mitogen-activated protein kinase pathways in mouse macrophages," *Immunopharmacology and Immunotoxicology*, vol. 38, no. 2, pp. 98–102, 2016.
- [25] C.-Q. Li, L.-C. He, and T. Deng, "Pharmacokinetics and tissue distribution of atractylenolide III in rats," *Zhong Yao Cai = Zhongyaocai = Journal of Chinese Medicinal Materials*, vol. 29, no. 8, pp. 807–809, 2006.
- [26] X. Jiang, S. Sun, and Y. Wang, "Research on the toxicity of Ephedra," Shandong Chemical Industry, vol. 46, no. 14, pp. 49-50, 2017.